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ABSTRACT
Remotely activated hydrogel-based biomaterials can maximize the therapeutic
effects by providing localized deliveries and minimizing off-target side effects. Smart
hydrogels respond to an externally applied stimulus by delivering therapeutic
molecules. While showing promise in releasing molecules in a precise spatial manner,
they do not inherently provide temporally dynamic delivery profiles (e.g., controlled
timing, rates, and sequences) required to direct sequences of biological events.
Biological processes are characterized by a sequence of events regulated by a
complex interplay of signaling factors. For example, in the instance of ischemia
(where a tissue no longer receives oxygen and nutrients due to a lack of blood
perfusion), the establishment of new vascular networks in/out of the ischemic tissue is
needed. To achieve this, angiogenic sprouts are instructed to emerge from existing
nearby blood vessels through the presentation of proangiogenic signaling factors from
the ischemic tissue. After entering into the ischemic tissue, angiogenic sprouts are
instructed to become mature blood-perfusing vessels through localized presentations
of pro-maturation signaling factors. In another coordinated biological process (i.e., the
wound healing process), specific progenitor cells are recruited to the injury site where
they must then be instructed to proliferate and differentiate into a robust population of
tissue-specific cell types. Spatially, temporally, and sequentially coordinated
presentation of cell-specific recruitment, proliferation, and differentiation factors are
critical to the proper therapeutic outcome. Thus, in treatments that require proper
wound healing and tissue re-vascularization, it is important to locally deliver
therapeutics in spatiotemporally nuanced manners while hydrogels are well-suited for

providing localized deliveries, traditional biomaterials not to provide the
spatiotemporally nuanced delivery profiles needed to direct spatiotemporally complex
biological processes, such as those that underly injuries and disease.
In addition to the regeneration of tissues and vascular networks in wound healing
applications, cancer treatments can potentially be improved through spatiotemporally
coordinated therapeutic deliveries. Localized deliveries of chemotherapeutics at tumor
sites, for instance, can reduce off-target side-effects of toxic chemotherapeutics, and
hydrogel-based materials are well-suited for providing these localized deliveries.
However, the localized and sustained deliveries provided by polymeric hydrogels are
not optimal for cancer treatments, especially regarding tumor cells’ abilities to develop
resistance to chemotherapeutic agents when subjected to constant chemotherapeutic
concentrations over protracted periods. Emerging cancer treatment strategies often
employ temporally dynamic deliveries of single or multiple anticancer agents to
prevent adaptive resistance and improve tumor regression.
In this dissertation, three types of polymeric hydrogel-based systems were
developed - i) calcium crosslinked alginate hydrogels, ii) biphasic alginate ferrogels,
iii) two-compartment hydrogel systems consisted of a gelatin outer compartment and
ferrogel inner compartment. These hydrogel-based biomaterial systems were
investigated to determine their potential for explicitly directing complex biological
processes by providing temporally complex therapeutic delivery profiles. For instance,
calcium-crosslinked hydrogels were subjected to short ultrasound pulsations (repeated
on/off) to minimize hydrogel erosion and temperature increase while providing
consistent and statistically significant chemotherapeutic release rates vs. time.

Additionally, the sequential release of anticancer agents was demonstrated. Pulsatile
mitoxantrone delivery profiles were also demonstrated from biphasic ferrogels when
exposed to graded magnetic fields. Chemotherapeutic release rates could be explicitly
controlled by stimulating at different magnetic field frequencies. Sequential release of
protein signaling factors was also demonstrated by incorporating these magnetically
responsive ferrogels into a compartmentalized hydrogel system. The outer gelatin
compartment resulted in burst release of one cytokine (GM-CSF, VEGF, SDF-1α),
whereas the inner ferrogel compartment provided on-demand, delayed the release of
separate cytokines (HSP27, PDGF, BMP2) when subjected to magnetic stimulations.
In both these ultrasonically and magnetically responsive gel systems, while hydrogels
were stimulated by external energy fields, a safe region of operation was maintained.
Ultrasound parameters (amplitude, frequency, duration, number of repeated pulses)
were chosen such that gel heating does not exceed 450C temperature (80C above body
temperature) critical for structural integrity of proteins and maintenance of biological
homeostasis. The ferrogel-based systems required that only simple, benign, hand-held
magnetics be used for stimulation and could be operated without thermally damaging
tissues.
In summary, stimuli-responsive hydrogels systems were developed here,
characterized, and demonstrated to provide a number of different therapeutic delivery
profiles that are likely to have beneficial impacts on treatment strategies. These
stimuli-responsive hydrogel-based biomaterials not only could generate these
temporally complex deliveries, but they also could be triggered to produce these types
of deliveries in an on-demand manner. This may be of particular clinical utility, in that

clinicians will gain the flexibility to alter the course of therapies in real time,
according to updates in patient prognosis. Finally, the hydrogel systems developed
here will enable rapid optimization of complex delivery strategies in cancer
treatments, wound healing, regenerative therapies, and in any treatment where control
over complex biological processes is needed for improved therapeutic outcome.
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PREFACE
This dissertation is written in the manuscript format. The first chapter is a general
introduction to the motivation and research objectives to address the problems stated
throughout this dissertation. The second chapter is a review of the literature on current
ultrasound-based drug delivery systems written as part of an invited review in
preparation to be submitted to the journal Acta Biomaterialia. The third chapter
entitled as “Ultrasonic generation of pulsatile and sequential delivery profiles from
calcium-crosslinked alginate hydrogels” is a published article in the “StimuliResponsive Polymeric Materials” special issue of journal Molecules (Molecules 2019,
24, 1048; doi:10.3390/molecules24061048). The fourth chapter entitled as “Pulsatile
Chemotherapeutic Delivery Profiles Using Magnetically Responsive Hydrogels” is a
published article on ACS Biomaterials Science and Engineering (ACS Biomater. Sci.
Eng. 2018, 4, 2412−2423; DOI: 10.1021/acsbiomaterials.8b00348). The fifth chapter
named as “Magnetically responsive biomaterial system enables on-demand, sequential
delivery of biomolecules for variety of biomedical applications” is a manuscript in
preparation for the journal Biomaterials Science. The final chapter includes primary
conclusions, importance, and future research directions related to this dissertation.
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CHAPTER 1

INTRODUCTION

1.1.

Background and Significance
A common treatment strategy for a vast array of injuries and diseases involves the

deployment of therapeutic agents (i.e., drug delivery), and is an every-growing and
ever-evolving field. For example, the fast-track pharmaceutical innovation resulted in
59 new FDA approved molecular entities in 2018—the highest rate of drug approvals
in 22 years [1]. Despite this wealth of therapeutics and more anticipated on the
horizon, the bench-to-bedside translation of these therapeutics is inherently limited.
Administration of drugs is fundamentally designed to enable control over the
biological processes underlying injury and disease. However, the biology that underly
injury and disease often involve spatially complex sequences of individual biological
events. Therapeutic control over these spatiotemporally complex processes thus
requires spatiotemporally nuanced therapeutic deliveries. In the following sections,
this fundamental roadblock will be discussed in two clinically relevant theaters: cancer
chemotherapies and re-vascularization in regenerative therapies.
1.1.1 Cancer Chemotherapy
Cancer brings immense sufferings to 2 million people every year in the USA (i.
e., one patient dies, and three new patients will be diagnosed with cancer in every
minute in 2019) [2]. In most cases, cancer is treated by oral or systemic administration
of chemotherapeutics. Traditional systemic administration is limited in its difficulty in

1

maintaining therapeutic drug concentration at tumor sites (i.e., maintenance of the
therapeutic window) and is plagued by off-target side effects due to the requirement of
repeated and large doses and toxic agents (chemotherapeutics are harmful to healthy
cells [3]). Implantable biomaterials can help reduce these side effects by releasing
drugs locally at the point of interest (i.e., the tumor site) [3-4]. Despite promising work
of localized drug deliveries from polymeric hydrogels, the deliveries provided by
these hydrogels are often not optimal. Traditional hydrogels release drug molecules in
a sustained manner and prevent altering the dose after implantation. This inherently
limits clinical flexibility (i.e., the ability to change therapies in real time). Moreover,
the relatively constant chemotherapeutic concentrations locally provided by these
hydrogels are highly amenable to the development of adaptive resistance [5].

Figure 1: The timing, rate, and sequence of anticancer deliveries are essential
parameters in cancer treatment. (A) MDA-MB-231 human breast cancer cells were
2

exposed to mitoxantrone delivery schedules S1 to S5 with same integrated dose in
vitro (i), percent viable cells (cell population normalized to untreated controls) over 3
days when exposed to schedule S1 to S5 (ii). Adapted from Huebsch et al. [6]. (B) A
murine mammary carcinoma mouse model was exposed to a different combination of
anticancer drugs- vehicle only, DTX only, DTX and Das simultaneously, and DTX
and Das sequentially (i, schedules 1 and 2), results of tumor growth rate (ii) and
percent survival (iii). Adapted from Goldman et al. [7]. Asterisks (**) indicate
statistically significant differences with p < 0.01.
There is growing evidence that adaptive resistance can be hindered by pulsatile
chemotherapeutic delivery profiles [5-7]. These pulsatile deliveries are inspired by
chronotherapy where highly concentrated drugs are applied during short timeframes
when tumor cells are most susceptible, but the rest of the body is less susceptible [89]. This strategy has been found to be effective because cancer cells have faster
metabolic cycles whereas the rest of the body has a slower metabolic cycle [8-9]. A
short burst of highly concentrated mitoxantrone deliveries has reported being more
effective in killing MDA-MB-231 human breast cancer cells in vitro than constant
flatline delivery of same integrated dose (Figure 1A, comparing the percent cell
viability of schedule S1 to schedules S2-S5). In addition to pulsatile deliveries, some
emerging cancer treatment strategies involve multiple therapeutic deliveries, often
delivered in sequence [7, 10-12]. It has been shown that 5-fluorouracil pre-treatment
increases the bioeffect of irinotecan on colon cancer cells [10-12]. Also, the timing of
second agent delivery plays an important role. For example, better tumor growth
reduction resulted in a mammary murine carcinoma model when dasatinib (Das) was

3

applied soon after docetaxel (DTX) administered rather than delayed application.
(Figure 1B, the percent of animal survival was highest for schedule S1 than schedule
S2 and simultaneous deliveries). These results motivate the need to develop a drug
delivery system that will enable sequential deliveries of multiple therapeutics so that
multi-drug delivery strategies can be rapidly optimized.
1.1.2 Re-vascularization in regenerative therapies
Tissue regeneration involves delivery of signaling factors for restoration and
functionalization of new tissues and organs. Natural tissue regeneration requires the
establishment of growth factor gradients where the timing and direction of these
gradients are key to regenerative outcome [13-15]. For instance, wound healing after
injury requires the establishment of vascular networks [16]. Growth and development
of vascular tissues requires the presentation of several growth factors at different times
[17]. Proangiogenic factors like vascular endothelial growth factor (VEGF) promotes
endothelial sprouting to the site that requires new vasculature (Figure 2A). VEGF, for
instance, enhances microvessel density by promoting pericyte cell detachment from
the vascular endothelium (Figure 2A, 2nd from left). This pericyte detachment
destabilizes the vessel, allowing the sprouting of a new, but small, vessel (Figure 2A,
3rd from left). This small sprout will continue to sprout, but not mature into a larger,
blood-perfusing vessel until pericytes are recruited back to the sprout through plateletderived growth factor PDGF signaling (Figure 2A, 4th from left). This re-recruited
pericyte stabilizes the sprout, allowing it to grow, thus facilitating the flow of blood
through the tissue (Figure 2A, furthest to the right) [18-19]. Therefore, the
development of mature vasculature requires sequenced delivery of pro-angiogenic
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factors followed by pro-maturation factors (e. g., VEGF followed by PDGF). This
motivates the need to develop effective strategies to deliver growth factors in
sequence. Besides wound healing applications, vascularization can potentially help to
treat cardiovascular diseases which are the leading cause of death in the USA in 2018
(in 38 sec one person dies by cardiovascular diseases) [20]. Tissue engineering can
potentially provide powerful strategies for treating a wide variety of cardiovascular
diseases by directing the growth of new or repairing defective vascular tissues.

Figure 2: Sequential VEGF and PDGF deliveries are required to produce new,
mature vasculature. (A) Schematic of natural angiogenesis and vessel maturation
5

process. Adapted from Brudno et al. [13]. (B) Comparisons of blood vessel area
distributions after administering the indicated combinations of growth factors.
Adapted from Richardson et al. [18].
Because of this perceived need to deliver both VEGF and PDGF for proper revascularization, pervious work has examined its potential. Richardson et al. [19]
designed a hydrogel system to deliver both VEGF and PDGF and investigated how
different combinations of VEGF and PDGF impacted vascular development and
maturation (Figure 2B). It was found that in an in vivo ischemic tissue model, the
percentage of matured (larger) blood vessels was significantly higher when delivering
PDGF only (Figure 2B, comparing ‘blank’ to ‘PDGF’). However, vessel maturation
was not significantly higher than for dual delivery of VEGF and PDGF comparing to
delivering PDGF alone (Figure 2B, comparing ‘Dual’ to ‘PDGF’). To understand
these results, it is important to note that these deliveries were not truly sequential.
While the gels used here were designed to deliver VEGF and PDGF and different rates
(i.e., with VEGF delivering at a higher rate than PDGF), starting at early time points,
both VEGF and PDGF were being delivered to the ischemic tissue. Thus, the
presentation of PDGF at the same time as VEGF likely negated the signal to form new
vessels (VEGF instructs pericytes to detach while PDGF instructs them to attach).
Thus, this conflicting instruction did not give significantly better blood vessel
maturation (as indicated by the lumen area distribution) than the system where PDGF
was added alone. These studies underscore the strong need for biomaterials that are
capable of delivering VEGF and PDGF in truly sequential manners. Furthermore, the
optimum time for delivering PDGF after VEGF is not yet understood. Depending on
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the disease, injury, or patient, this timing will likely be different. Moreover, the timing
and dose for delivering growth factors in clinical situations may need to be altered in
response to up-to-date diagnostic information. Being able to remotely and flexibly
control these sequential deliveries without changing the biomaterial construct will
provide clinical and investigative advantages.
1.2.

Research objectives
The principal objective of this study was to develop hydrogel-based systems

capable of delivering therapeutic molecules with real-time control over the release
profiles, timings of release, and release sequences by external stimuli. The four
following objectives were designed to address this overarching principle objective:
Objective 1, Review and understand the use of ultrasonic stimulation for
regulating drug delivery profiles from hydrogels.
Objective 2, Develop, characterize, and demonstrate the use of ultrasonically
responsive hydrogels for generating pulsatile and sequential delivery profiles.
Objective 3, Investigate the impact of pulsatile anticancer treatment profiles on
tumor cells in vitro and reproduce the optimized temporally controlled deliveries
(pulsatile profiles) from magnetically responsive hydrogels.
Objective 4, Develop and demonstrate sequential release profiles of various
protein signaling factors from hydrogel systems containing magnetically responsive
hydrogels.
This dissertation was intended to uncover critical information needed to push
stimuli-responsive biomaterials towards use in clinical scenarios. This work will
provide fundamental characterizations on how gels release their payloads in response
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to remotely applied stimuli. For example, drug release from these hydrogels will be
characterized in terms hydrogel formulation (polymer and crosslinker concentration,
type of crosslinker, mechanical strength, porosity, swelling ratio), molecule properties
of the payload (molecular weight, charge density, polarity, hydrogel polymermolecule affinity, amount of drug remaining in the gel vs. time), stimulation
parameters (intensity, duration, number of repetitions, frequency, the type of stimuli
(magnetic vs. ultrasonic, for example)), and physical alterations to the gel system over
time (temperature vs. time, gel deformations, gel erosion). These extensive
characterization can reveal new strategies for generating temporally complex delivery
profiles (i.e., pulsatile and sequential). Subsequent demonstrations of pulsatile and
sequential deliveries combined with in vitro tests proving that pulsatile and sequential
deliveries can improve therapeutic outcome will provide ctirical ‘proof of concept’
data. Taken altogether, this lays the groundwork for potential improvements in
treatment strategies in far-reaching applicatoins, including, but not limited to
chemotherapies, regenerative therapies, wound healing, cancer immunotherapies, and
beyond.
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CHAPTER 2

REVIEW OF LITERATURE

2.1.

Introduction
Ultrasound has a long successful journey in diagnostic imaging applications for

monitoring internal tissues in the clinics. Because of its relatively safe, portable,
affordable and patient compliant facilities, it’s been adopted for therapeutic purposes.
In 1954, Fellinger and Schmidt showed that the higher penetration of hydrocortisone
with ultrasound for bursitis and tendinitis treatments [21]. In the 1980s, lithotripsy
rapidly replaced surgical kidney stone removal that used high-pressure amplitude
shock waves [22]. Ultrasound has a high spatiotemporal resolution that’s why it has
been used to deliver high and low molecular weight proteins, DNA, and gene by
invading deep tissues. It is possible to deliver drugs from a payload using ultrasonic
stimulation to tissues like the heart, lungs, brain, blood vessels, skeletal muscle, bones,
tumors, fetus, etc. Some of ultrasound-based FDA approved treatments include tumor
ablation (prostate, uterine fibroid, kidney), adipose tissue removal (ultrasound assisted
liposuction), cataract removal (phacoemulsification), transdermal drug delivery,
wound and bone healing, hemostasis, analgesia. Ultrasound can be divided into two
types: low-intensity ultrasound (20 kHz-100 kHz) and high intensity focused
ultrasound (2 MHz-16 MHz). Low-intensity ultrasound undergoes vigorous cavitation,
causes a lower temperature increase, has better tissue penetration, and longer
wavelengths make it difficult to focus. [23-26] On the other hand, high frequency
focused ultrasound (HIFU) has a very precise focal site where the temperature can
12

increase (up to 60-80oC) rapidly (within 1-20 sec) results in drug carrier perturbation
and thermal lesion on tissues [22, 27-28].
There are several commercially available US FDA approved ultrasound devices
and products. Sonotherm 1000 (Labthermics Technologies, Inc.) is an ultrasonic
hyperthermia device for cancer treatment received approval in 1989. Since then, tools
like Exogen 2000+ (Smith & Nephew) for bone healing, SonoPrep (Sontra Medical
Corp.) for topical anesthesia, Contour Genesis (Mentor Corp.) for the Lipoplasty
device, Shinmed SW-988 (Shinning World Health Care) an ultrasonic nebulizer, etc
received market approval in last three decades. ExAblate 2100 (InSightec) and
Sonoalleve (Philips) are two instruments that use HIFU to cancer treatment and pain
relief. ThermoDox (Celsion Corp.) is a liposome containing doxorubicin that releases
by HIFU received FDA approval on 2014 for treating liver cancer.
Although therapeutic ultrasound treatment has well-defined benefits, some
undesirable burning and tissue injury may happen because of accumulating a
substantial amount of energy to localized areas. Some adverse effects include
bleeding, scarring, and infection [22]. Standardization of ultrasound dosimetry and
experienced operator can potentially manage the side effects. American Institute of
Ultrasound in Medicine provides guidelines for a safe window of parameters. Careful
consideration of bioeffects caused by these parameters ensures safe therapeutic
applications that lead to government-approved devices and products for clinical
practice.

13

2.2. Mechanism
The biological effects caused ultrasonic energy on cells and tissues can be
discussed into two mechanisms:
2.2.1 Hyperthermia
Acoustic waves by ultrasound propagate at a predetermined intensity where a
portion of the energy converts into heat during irradiation. The rise of temperature can
be very rapid varying from material to material due to different coefficients of
ultrasound absorption. This elevated temperature can break the biomaterials carrying
drug (nanoparticles, liposomes, micelles, hydrogels) [3, 29-34] (Figure 1, nanocarriers
(yellow) in the depot releasing drug molecules after getting hit by US beam). The US
also increases the temperature of the surrounding tissue that can be calculated by the
bioheat transfer equation [28]. Hence, US-induced heating with the unfocused beam is
used in physical therapy to fast temperature elevation to tissues like bone [35-36].
Hyperthermia-based heat elevation is widely used for tumor ablation. Tumor tissues
are inherently acidic, stressed by low oxygen levels, nutrient deprived, less tolerable to
additional stress caused by elevated temperature. Heat dissipation by ultrasound is
cytotoxic for tumor cells compared to normal cells due to their dense vascular growth
[37]. It is reported that an ultrasound wave at frequency 1 to 3.4 MHz for 30-60 min
can increase tumor temperature uniformly to 42-45oC and reduce its growth [38-39].

14

Figure 1: High intensity focused the US can release drugs by increasing temperature
on the point-of-interest precisely. Here, a nanocarrier (yellow) is disrupted by HIFU
and exploded to release drug molecules (red). The explosion also causes degradation
of the depot.
The applications of hyperthermia-based ultrasound have been modified into high
frequency focused ultrasound (HIFU) because of its precise temporal and spatial
control. Targeted drug delivery from nano-carriers by ultrasonic hyperthermia is a
promising field of research [40]. Temperature sensitive liposomes (TSL) was at first
introduced in 1978 by Yatvin et al. for drug delivery by phase transition of lipids [33].
The increased cellular uptake of TSL into cancer cells happen by targeting drugloaded liposomes into the tumor sites by passive accumulation and preferential
extravasation of tumor blood vessels (EPR effect) [41]. Ultrasound-assisted
hyperthermia triggers drug release from TSL in the tumor vasculature and interstitium.
Some liposomes can revert to its previous phase when not irradiated and seals away
any unreleased drug [42]. Dromi et al. used single focus pulsed HIFU (ISATA=1300
W/cm2, 120 pulses, 1 Hz, duty cycle 10%) to release doxorubicin from ThermoDox®
in a murine mammary adenocarcinoma BALB/c model for 4-50C temperature
15

elevation in 15-20 min [43]. Patel et al. used a split focus transducer (TAT 80 W, 120
s pulsed, 1 MHz duty cycle 10%) to release doxorubicin from ThermoDox® in a
murine squamous cell carcinoma SCC7 model for 4-50C temperature elevation in 2
min [29].
HIFU has been recently coupled with MRI for better tissue differentiation and
real-time monitoring of temperature changes by focused ultrasound [44]. Smet et al.
released doxorubicin from a TTSL formulation of ThermoDox® and MRI contrast
agent Gd-HP-DO3A (H2O) with MR-HIFU clinical system (ISATA=117 W/cm2,1.4
MHz, continuous pulses for 15 min twice) at 41.5±0.5 °C in a rat tumor model [32].
Negussie and Ranjan et al. found better doxorubicin distribution in the tumor core and
periphery using an LTSL with doxorubicin and Gd-HP-DO3A stimulated by an MRHIFU clinical system (1.2 MHz, 10 min heating, 5 min cooling twice) in a Rabbit
VX2 tumor model [30-31]. Staruch et al. released doxorubicin from ThermoDox® in
a Rabbit bone marrow muscle by MR-guided mechanical scanning (2.8 MHz, 2.5
MPa) at 43oC for 20 min [34].
2.2.2 Cavitation
Cavitation is the dominant reason for the enhanced convection and diffusion by
ultrasound [45]. The oscillating media can increase the transport of molecules. This
effect can be enhanced by several orders of magnitude if gaseous cavities exist.
Formation, growth, and activities of gas-filled cavities are known as cavitation. Stable
cavitation involves periodic growth and oscillations of gas bubbles whereas inertial
cavitation involves rapid growth and collapse of gas bubbles [46]. Stable cavitation
creates acoustic streaming and shear forces on tissues, and inertial cavitation generates
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shock waves that can produce very high shear rates to surrounding tissues drug
carriers [47]. Pressure gradient in the surrounding fluid of the bubble leads asymmetric
collapse that ejects a liquid microjet at a sonic speed capable of penetrating tissues
[46]. The mechanical effects exerted by cavitational ultrasound can be used for
therapeutic purposes which are discussed below,
2.2.2.1 Enhanced convection and diffusion
The oscillatory motion of the collapsing bubbles capable of inducing transport in
the media, extracellular matrix and blood. The continuous growth and collapse of
bubbles can make high viscous shear rates around the surface of the bubbles that
increase the diffusion coefficient of any drug [48]. This enhanced transport affects the
nanocarriers by attracting them to the area of microstreaming due to density difference
(nanocarriers usually have a higher density). When the nanocarriers reach that area,
they are sheared open by microjets (Figure 2, drug-carrying vesicles are breaking by
cavitation effects of US and releasing drug molecules from the depot). This effect
depends on the degree of oscillations in the area and can be very useful for targeted
drug delivery [48-49]. A large number of studies showed enhanced delivery of low
and high molecular weight drugs, radionucleotides, siRNA, plasmid DNA into deep
muscle tissue (ovary [50], kidney [51]), ocular tissues (retina, cornea) [52], cardiac
tissue [53], and brain tissue [54] in vivo. Fujii et. al. treated myocardial infarction in
Sprague-Dawley rats by targeted delivery of stem cell factor (SCF) and stromal cellderived factor (SDF-1α) from pcDNA3 plasmid DNA with DEFINITY® microbubbles
using US (15L8 transducer, mechanical index 1.6, 1800-2000 ms bursts for 20
min/day up to 10 days, 2 days interval) [55]. Shimoda et. al. reported revascularization
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of islet cells and restoration of euglycemia in transplanted islet cells in diabetic mice
to treat type 1 diabetes by non-viral plasmid vectors delivering VEGF165 gene by a
commercial ultrasound transducer (S3, Sonos 55000; 1.3 MHz, mechanical index 1.4,
4 bursts with 85 ms delay) [56]. Chandan et al. delivered paclitaxel to murine B16F10
melanoma tumor model in C57BL/6 mice from phosphatidylserine-liposomenanobubble conjugates (PSPLBC) using US (SP100 sonoporator, 2 W/cm2, 50% duty
cycle, 60 s) immediately after administration of the formulation [57].

Figure 2: Cavitation in the bubbles can release drug molecules when irradiated with
the US. Several cavitation phenomena, i.e., microstreaming, shock waves, and
microjets are responsibly increasing the transport of molecules from the depot.
2.2.2.2 Disruption of the drug carrier
Drug carriers like liposomes, micelles, microcapsules, and hydrogel micro
composites, etc. are susceptible to ultrasound-induced cavitation. They carry a payload
to tissues and release drugs when irradiated. Stable oscillation attracts them to be
diffused to the region of interest. Shock waves and microjets can pierce through the
vesicles [47-49, 51, 53, 55-57] (Figure. 2). Kwok et al. introduced an ultrasound
responsive coated pHEMA hydrogels for insulin delivery that can reseal itself and can
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be used up to 5 days [58]. Liposomal vesicles usually get partially restored which can
maintain a sustained release [59-60]. When a drug is not entrapped but attached to the
polymer backbone of the carrier, the ultrasonic effect can be seen to pull apart the drug
molecules by breaking polymeric chains [60]. Epstein-Barash et al. co-encapsulated
liposomes with perfluorocarbon (PFC) microbubbles in an in situ crosslinking
hydrogels in male CD-1 mice and triggered release of trypan blue dye using a 20 kHz
US (100% duty cycle, 0-10 W/cm2, 0-15 s intervals) [61].
Ultrasound can be very useful for cancer treatment because of its ability to locally
deliver chemotherapeutics and induce apoptosis [62-63]. Nelson et al. found reduced
tumor volume by delivering doxorubicin from Pluronic NanoDeliv™ micelles to colon
carcinogenic DHD/K12/TRb inoculated rat model by continuous and pulsed US (1-2
W/cm2, 20-70 kHz, one h/week up to a month) [64]. Howard et al. found 90% cellular
proliferation of tumor by releasing paclitaxel from SYP-PM micelles to the
MDB7/ADmt breast cancer cell lines in vitro and in vivo in nu/nu mice with US (1
MHz, 1.7 W/cm2, 33% duty cycle, 30-90s durations) [65]. Ultrasound is not only
destructing the nano/microvesicles to release payloads; it is also able to liberate
payloads from scaffold-based drug depots. Huebsch et al. introduced a seal-healing
injectable Ca2+ crosslinked alginate hydrogel system to trigger the release of
mitoxantrone in MDB-MB-231 and MCF7 cell lines and tumors on Nu/J mice models
and the US (VCX130 Sonicator, 120 mW/cm2, 2.5 min/d) [6]. They also showed these
hydrogels could be used to release cytokines VEGF165 and SDF-1σ without altering
their bioactivity [6].
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2.3. Tunable parameters
2.3.1 Sonication time, frequency and intensity
Inertial cavitation is directly related to the sonication time (Figure 3A), frequency
(Figure 3B), and acoustic pressure amplitude/intensity

[26, 66-73]. Initiation of

cavitational nucleation requires a minimum threshold ultrasound intensity at a given
frequency up to a certain decoupling frequency [26, 73]. Beyond this decoupling
intensity, cavitation does not increase with increasing intensity due to acoustic
decoupling. The threshold frequency increases with increasing frequency because the
growth of bubbles becomes difficult at a certain intensity (Figure 3C). Tezel et al.
formulated that energy density can be calculated by multiplying the intensity and net
exposure time [26]. At a constant intensity, low frequencies can penetrate more deep
tissues than higher frequencies [66, 73]. Increasing the US power intensity directly
increases the release of payloads [57, 66, 68, 70, 72-74].

Figure 3: Skin conductivity enhancement of sodium lauryl sulfate due to the presence
of the US is a function of time, frequency, and energy density. (A) Plot of conductivity
enhancement vs. time at 36.9 kHz frequency at intensities 0.54 (□), 0.60 (∆), 0.84
(■),0.96 (◊), 1.08 (●),1.26 (○) W/cm2. (B) The plot of conductivity enhancement vs.
frequency. (C) The plot of conductivity enhancement vs. energy density at frequencies
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19.6 (●), 36.9 (○), 58.9 (■), 76.6 (□) and 93.4 (▲) kHz. Adapted from Tezel et al.
[26].
Jiang et al. found the release concentration of mimosa drug from 1 wt. %
cellulose in dimethylacetamide (DMAc/LiCl) hydrogel film increased with increasing
US intensity and exposure time at constant 43 kHz frequency (Figure 4A, release
were higher at 30 W intensity than at 5 W intensity) [72]. They also reported 1.4 times
higher rate of mimosa release at a lower frequency when tested at a constant 10 W
intensity (Figure 4B, 23 kHz frequency resulted in a higher rate than 96 kHz
frequency) [72].

Figure 4: Mimosa release concentration in the aqueous solution of the US is a
function of (A) time and intensity at constant 43 kHz frequency and (B) time and
frequency at constant 10 W intensity. The 1 wt.% cellulose hydrogel film was made
from the solution with 0.08 wt.% mimosa. Adapted from Jiang et al. [72].
Wu et al. reported the release of bovine serum albumin (BSA) from Nisopropylacrylamide (NIPAM) and N,N’-methylenebisacrylamide (MBAm) hydrogel
increased significantly when US intensity risen from 0.55 to 3 W/cm2 (1 MHz
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frequency, 30% duty cycle, for 3 min) [74]. They used temperature control water bath
to maintain the temperature of control same as US group to ensure the release were
only due to the US, not due to elevated temperature inflicted diffusion by US [74].

Figure 5: Release of BSA from NIPAM/MBAm (3.0/0.02 g/g) hydrogels varied with
different intensities of the US. The elevation of temperature by the US was kept
similar to the controls by water bath heating to eliminate the effect of temperatureinduced diffusion. Adapted from Wu et al. [56].
Kennedy et al. showed ultrasonic pressure amplitude has a direct relationship
with the release of iron oxide microparticles from alginate capsules [68]. At 80%
amplitude for 2-sec irradiation made an effect equivalent to 4-sec irradiation of 40%
amplitude. The 20%, 40%, and 80% amplitude were reported to be equivalent to 1.8,
6, and 7.4 W/cm2 power intensity respectively depending upon the sonicator [68].
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Figure 6: Photographs of the release of iron oxide particles in the PBS solution from
alginate capsules when sonicated at various US signals for 5 sec. The 13 cm US probe
was placed 2 mm above the capsules in glass scintillation vials. Images adapted from
Kennedy et al. [68].
2.3.2 Effect of transducer type and position
The effects of US vary with the diameter, shape, and distance from the transducer
crystal [66, 75-77]. The area of the US field beam is not uniform and changes its
nature with distance. The energy of the US beam spreads as it propagates through the
material. Therefore, the maximum effects found in the area directly in front of the
transducer. Beam spread is higher for low frequencies (Figure 7A) and can be reduced
by increasing diameter (Figure 7B) of the transducer [75-76]. Rectangular transducers
have linear waves parallel to each other; on the other hand, convex transducers have
wider waves with increased depth [78].
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Figure 7: The beam spread varies with the diameter and frequency of US. (A)
Simulated images of beam spread at 1, 5, and 9 MHz frequencies from a 0.75-inch
diameter transducer, (B) images of beam spread at 50 kHz frequency from transducers
of 3, 7, and 10 mm diameter. Adapted from the NDT resource center webpage [75].
The position of the drug depot also plays an essential role in effective payload
release. The closer is the position of the depot to the transducer, the higher is the effect
of US Kennedy et al. found that less energy was required to get iron oxide release
from subcutaneously implanted hydrogels in the chicken carcass tissue models than in
the scintillation vials [68]. When tested in scintillation vials, a portion of the US
energy gave kinetic energy to the particles to bounce in PBS [68].
2.3.3 Pulse number and pulse ratio
Pulse number and pulse ratio are found to be influencing parameters for drug
delivery. Introducing several stimulations in a fixed time frame instead of one
continuous stimulation was found to be more effective in releasing payloads [29, 43,
65]. The seal-healing Ca2+ crosslinked alginate hydrogel used by Huebsch et al. was
found to be effective in the in vivo tumor models up to 2 weeks for repeated irradiation
because the scaffold reverted its structure when not irradiated [6].
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Pulse ratio is often expressed as a duty cycle where a 20% duty cycle or pulse
ratio 1:4 means keeping the machine on for one unit and off for four units. 100% duty
cycle refers to continuous stimulation whereas 10% duty cycle is the least exposure to
irradiation [66]. Wang et al. was able to increase the release rate of diclofenac from
alginate microcapsules by 16% compared to non-US by using six pulses (Figure. 8)
[70].

Figure 8: Release of diclofenac from alginate microcapsules is a function of pulse
number and ultrasound power. US was applied at 1.2 MHz frequency, 1 W, 5 W, 9W
intensities with 30 sec period. Adapted from Wang et al. [70].
2.3.4 Biomaterial construction
Design of a drug carrier plays a role to enable more control over the payload
release. Different formulations of scaffolds and nanocarriers were proposed to get the
spatiotemporal on-demand release of payloads. Coated hydrogel film [58], hydrogel
micro-composite with nanocarriers and liposomes [61, 67-68, 70], coated
nanoparticles [69], micelles [64-65, 71], liposome nanobubble conjugate [57] are some
reported examples where encapsulated drugs underwent prolonged therapeutic
delivery for several days to months. Wu et. al. found the higher release of BSA (66
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kDa) with the US when the amount of NIPAM in the NIPAM/MBAm hydrogel was
increased to 3 g from 1 g due to high-temperature coefficients of denser gels aided
more pore channel formation in the gel matrix than less dense gels [74]. On the other
hand, Jiang et al. reported lower polymer concentration of cellulose in DMAc/LiCl
hydrogel film aided increased release of the mimosa drug than higher concentrations
of cellulose [72]. This group suggested the enhancement of the release is due to the
mimosa-water and mimosa-cellulose hydrogel bond breaking by the US (Figure. 9).
Thereby the 0.5 wt% of cellulose was less rigid than 2 wt% that can be disrupted
easily with the same amount of energy [72].

Figure 9: Plot of mimosa release concentrations with time when subject to varying
cellulose concentrations. 30 W ultrasound was irradiated at 43 kHz frequency for
various exposure time. Adapted from Jiang et al. [72]
Kearney et al. showed that the increased surface-to-volume ratio of the hydrogels
increases the ultrasound dependent release of nanoparticles rather than degradationbased release from the scaffold. The cumulative release of PEGlyted gold
nanoparticles (AuNP) from Ca2+ crosslinked alginate microbeads of d~250 µm
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(Figure 10B) were higher than alginate hydrogels (Figure 10A). Increased surface-tovolume ratio provided PEG-AuNPs less distance to get liberated from the matrix when
subjected to US [67].

Figure 10: Cumulative release of PEG-AuNPs from (A) alginate hydrogels and (B)
alginate microbeads using 9.6 mW cm-2 US for 2.5 min h-1 up to 5 hrs following
overnight storage at 370C. TEM images are showing that the media only had isolated
NPs after the US but no gel fragments. Adapted from Kearney et al. [67].
Concentration and composition of coatings on nanoparticles can help to tune the
release kinetics. Kennedy et. al. synthesized weak and strong hydrogel capsules by
using 50 mM CaCl2 and 100 mM BaCl2 crosslinkers respectively that released their
payloads selectively at 20% and 80% pressure amplitude of a 20 kHz signal
(equivalent to 1.8 and 7.4 W/cm2 energy intensity respectively) ultrasound (Figure 11)
[68].
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Figure 11: Alginate capsules of varying strength released AuNP particles at different
US power. (A) microscopic images of weak and strong capsules made with 50 mM
CaCl2 and 100 mM BaCl2 crosslinkers respectively. (B) Percent AuNP release with
time when stimulated at 20% (i) and 80% (ii) ultrasonic power amplitude. Adapted
from Kennedy et al. [68].
On the other hand, Moncion et al. reported that double emulsion perfluorocarbon
(PFC) microbubbles in fibrin scaffold required more acoustic thresholds than its single
emulsion formulations [79]. Beyond a specific US amplitude, PFC within these
emulsions can undergo a phase transition from liquid to gas. The power required to
initiate cavitation varied for single and double emulsion formulations [79].
2.3.5 Effect of microbubbles
The presence of microbubbles in the scaffold influences the rate of cavitation.
PFC microbubbles have been used for DNA and gene therapy with ultrasound [53-55,
57, 60]. Epstein-Barash et al. incorporated perfluorobutane microbubbles and dyecontaining liposomes in the hydrogels [61]. The increased concentration of the PFC
microbubbles in the hydrogels increased cavitation, reduced US intensity and duration
yielding less tissue injury [61]. Type of microbubbles determines the power required
to initiate nucleation sites. Moncion et al. used two types of PFC microbubble
emulsions, perfluoropentane (PFP) and perfluorohexane (PFH) in the fibrin hydrogels.
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Hydrogels with PFP and PFH were found to have different threshold pressures (2.5
MPa and 3 MPa respectively) for acoustic droplet vaporization and initial cavitation
when ultrasonically irradiated [79].
2.4. Complex profiles
2.4.1 Existing strategies
US-based treatment mostly offers burst release immediately after irradiation [28,
35-36]. After a few hours of treatment, the effect of the drug in the area of interest
diminishes by body’s hepatic and renal clearance [57, 61]. The depletion of drug from
the depot in a sustained manner provides an opportunity for the cancer cell to develop
adaptive resistance [5]. There is evidence that complex drug release profiles are
advantageous over continuous release for tumor size reduction [11, 80]. Pulsatile
doses (several on/off ultrasound pulses) spreads out the US energy into short segments
which avoids burst release of drugs and excessive blood vessel extravasation [6, 57,
69-70]. The most important advantage of applying pulsatile dose on tumor tissue is
avoiding adaptive resistance of cancer cells and increase the cytotoxicity of anticancer
drugs [5]. The US-responsive C12 methylene chains coated pHEMA/PEGDMA
hydrogels described by Kwok et al. was found to be released insulin for five days in
therapeutic range at 1.1 MHz US pulses (for 5 min twice a day) and maintained
minimum leaching rate when not stimulated (Figure 12A) [58].
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Figure 12: (A) Release of insulin from methylene chains-coated pHEMA/PEGDMA
matrices when exposed to 1.1 MHz in the US for 5 min. Adapted from Kwok et al.
[58]. (B) Trypan blue release from liposome-microbubble conjugate in hydrogels in
vivo when subjected to US of 6 W/cm2 intensity for 1 min. Adapted from EpsteinBarash et al. [61].
Epstein-Barash et. al. was able to get triggered release of trypan blue dye for 2
weeks by injecting hydrogels (Figure 12B) with dye-containing liposomes and
microbubbles in vivo and using a short pulse with a relatively low-intensity (six
pulses, 10 sec on and 1 sec off, 48 h interval) [61]. Huebsch et al. presented a high
concentration mitoxantrone dose of 28.8 ug/min to the MDB-MB-231 and MCF7 cell
lines for a short time of 2.5 min/12 h and repeated for five days. This profile was able
to keep the lowest viability of cell (less than 10%) compared to the sustained release
profile of the same integrated dose. (Figure 13) This group achieved significantly low
tumor volume on Nu/J mice models on both short-term (8 days) and 50% survival
after long-term (180 days) experiments of 2.5 min/d pulsatile dose for [6].
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Figure 13: Effect of mitoxantrone dose profiles on the viability of cancer cells. (A)
schematic representation of sustained vs. pulsatile dose having the same integrated
dosing amount. (B) Fluorescence micrographs MDA-MB-231 breast cancer cells
exposed to a sustained mitoxantrone dose (Center) or a lower baseline drug dose with
a periodic high dose, applied for 10 min once every 12 h (right). (C) Cell viability in
MDA-MB-231 (blue) and MCF7 (red) breast cancer cell lines treated with sustained
or pulsatile exposure to mitoxantrone. Adapted from Huebsch et al. [6].
Wu et. al. was able to get on-demand triggered release of large and small
molecules BSA (66 kDa) and dextrans (3-5 kDa) from NIPAM/MBAm hydrogels
(Figure 14A) when stimulated with 2 US pulses of 3 min duration (1 MHz, 30% duty
cycle at 3 W/cm2) [74]. Wang et al. tested the anti-inflammatory effect of diclofenac
loaded alginate microcapsules in the carrageenan-induced rat paw edema models with
the US. The short US pulses of high intensity 9 W for 60 min in a pulsatile manner
(Figure 14B) (two irradiations of 3 pulses, 2 min on, 4 min off with an interval of 24
min) was able to lower the inflammatory inhibition by 81% [70].
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Figure 14: Cumulative release of (A) BSA (left) and dextran (right) from
NIPAM/MBAm hydrogels [74] and (B) diclofenac from alginate microcapsules [70]
when subjected to pulsatile US irradiations. Adapted from Wu et al. [74] and Wang et
al. [70].
The PSPLBC loaded paclitaxel drug to melanoma tumor model in C57BL/6 mice
described by Chandan et. al. resulted in 100% survival rates after 2 weeks that
incorporated 5 doses of the drug on every 3rd day with immediate administration of US
(2 W/cm2, 50% duty cycle, 60 s) [57]. Kearney et al. was able to get a switchable
PEGlyted AuNP release on demand from alginate hydrogels over multiple days (on
day 1 and day 5) with five 2.5 min/h US pulses of 9.6 mW/cm2 intensity. During the
incubation time, the group reported baseline diffusive release of 1-4% AuNP (Figure
15) whereas the US-induced 200-fold and 5000-fold higher release respectively on day
1 and day 5 [67].
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Figure 15: Cumulative release of PEG-AuNPs from alginate microbeads using 9.6
mW cm-2 US for 2.5 min h-1 up to 5 hrs following five days of storage at 370C.
Adapted from Kearney et al. [67].
Kennedy et al. also reported higher retention of AuNP payload in the alginate
capsules when not stimulated.100% The release was obtained on day seven after 100
sec US stimulation (20% amplitude of a 20 kHz signal) which exhibited a similar
release profile as day 1 [68]. This group demonstrated a sequential release of iron
oxide particles from weak and strong capsules (50 mM CaCl2 and 100 mM BaCl2
respectively) loaded in 2 wt.% alginate hydrogels in tissue model by 20% and 80%
amplitude of a 20 kHz signal in for 10 sec [68].
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Figure 16: (A) Percent AuNP release vs. time for when weak and strong capsules
were exposed to ultrasound for 200 s on day seven at 20% amplitude followed by at
80% amplitude for 100 s five minutes later. (B) Images of the release of iron oxide
loaded capsules integrated into Ca2+ crosslinked alginate hydrogels when subjected to
US stimulation under the chicken carcass model at 37oC. Adapted from Kennedy et al.
[68].
Instead of degradation based sustained drug release profile, a pulsatile profile can
be optimal for cancer tumor treatment whereas sequential release can be useful for
tissue engineering application like bone regeneration, wound healing, and
vascularization, etc. that require presentation of multiple agents to functionalize
properly.
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2.4.2 Prospected strategies
Using tunable parameters such as frequency, intensity, exposure time, gel
construction several treatment strategies can be designed.
a. Scaffold with strong capsules
There is evidence that sequential administration of 5-fluorouracil (5FU) and
irinotecan can be more cytotoxic to pancreatic cancer treatment [10, 12]. A system can
be developed to release two anti-cancer drugs from a single scaffold sequentially on
different days (Figure 17A). For example, A hydrogel can be designed to release 5fluorouracil at first by diffusion for few days while retaining the irinotecan loaded
strong microcapsules crosslinked by BaCl2 as suggested by Kennedy et al. [68]. When
5FU is depleted US can disrupt the microcapsules to release irinotecan with precise
temporal control.
b. Scaffold with differently sized PEGlyted AuNPs
A depot can be designed to release multiple agents selectively by tuning the size of the
NP containing microbeads (Figure. 17B). Smaller PEGlyted AuNP in alginate
microbeads were more responsive to the US than bigger AuNPs [67]. For example,
100 nm, 60 nm, and 30 nm diameters of AuNP can be incorporated with multiple
agents where the different intensity of US can selectively release different agents.
c. Two compartment scaffold
Two-compartment scaffold with different release kinetics can be fabricated. A
concentric cylindrical two-compartment structure can be useful for cancer treatment
where the outside matrix can be made with low polymer concentration for proapoptotic drug release with low-intensity US (Figure 17C). The inner compartment
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made with high polymer concentration that can retain the drug long-term and will
release on-demand high intensity focused on the US.

Figure 17: Prospected strategies for improving the release profiles by US stimulation.
(A) Scaffold with strong capsules, (B) Scaffold with differently sized PEGlyted
AuNPs, (C) Two compartment scaffold, (D) Scaffold with strong capsules, (E)
Scaffold with microbubbles and strong capsules.
d. Scaffold with strong capsules
A scaffold with twice as much strength than 2 wt % Ca2+ crosslinked alginate
hydrogels responsive to the US may provide prolonged release of growth factors
(Figure. 17 D). For bone regeneration, wound healing and vascularization, a scaffold
with GF 1 can help the nascent cell to grow, where GF 2 released from stronger
capsules by the US will aid the regeneration process.
e. Scaffold with microbubbles and strong capsules
A release profile can be tailored by incorporating microbubbles with drugcontaining nanocarriers. For example, a strong nanocarrier (liposome, micelles,
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microbeads) can be ruptured by cavitating microbubbles (Figure 17E). Microbubbles
also used for DNA and gene therapies on-demand with US-irradiation [53-55, 57, 6061].
Drug delivery from a depot by ultrasonic stimulation largely depends on the
degradation of the polymer matrix. Uncontrolled leaching by any unpredicted burst
release may cause clinical toxicity to patients. Hence, depot should have robust
structural integrity to maintain low baseline release when not stimulated.
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3.1.

Abstract
Control over of biological processes can potentially be therapeutically regulated

through localized biomolecular deliveries. While implantable hydrogels can provide
localized deliveries, they do not traditionally provide the temporally complex delivery
profiles required to regulate complex biological processes. Ionically crosslinked
alginate hydrogels have been shown to release encapsulated payloads in response to a
remotely applied ultrasonic stimulus, thus potentially enabling more temporally
complex delivery profiles. However, thorough characterizations of how different types
of molecular payloads are retained and ultrasonically released need to be performed.
Additionally, the impact of potentially disruptive ultrasonic stimulations on hydrogel
structure and temperature need to be characterized to better understand what range of
ultrasonic signals can be used to trigger release. Finally, experiments need to be
performed demonstrating that ultrasonic stimulation can be used to generate release
profiles demonstrated to have potential therapeutic benefits (e.g., pulsatile and
sequential anticancer delivery profiles). This work addresses the above-described
needs and underscores the potential of using ultrasonically responsive polymeric
hydrogels for improving drug delivery treatment strategies.
3.2.

Keywords
Ultrasound; on-demand release; cancer therapy; drug delivery; biomaterials.

3.3.

Introduction
Biological systems conduct themselves with high degrees of spatial and temporal

complexity. Many of the biological processes that underlie injury and disease
constantly change in space and time and must be regulated with spatiotemporal
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precision for proper therapeutic outcome. For instance, wound healing and tissue
engineering applications involve complex cell instructions where the spatial gradient,
timing, and sequence of bioactive molecules are vital to orchestrating proper tissue
regeneration [1-5]. Regeneration of tissues requires the generation of vascular
networks. This involves initializing angiogenic sprouting from nearby existing
vasculature (through the establishment of pro-angiogenic signaling factor gradients
emanating away from the regeneration site). After these sprouts have invaded the site
of regeneration, they must mature into larger, blood-perfusing vessels (through
localized presentations of pro-maturation signaling factors) [1-2]. Regenerating tissues
also demands the establishment of tissue-specific cells types, requiring recruitment of
progenitor cells to the injury site (through the establishment of recruitment factor
gradients emanating away from the injury site). Then, these recruited progenitors must
be directed to proliferate and differentiate (through localized presentations of
proliferation and differentiation signaling factors) [3, 6-9]. Beyond regenerative
therapies, cancer treatment strategies often aim to present anticancer therapeutics
locally at tumor sites to minimize off-target side effects and polymeric hydrogel
materials can be used to provide this localized delivery [10]. However, there is
growing evidence that the localized and sustained deliveries provided by hydrogels are
not optimal and may be particularly not well-suited for preventing adaptive resistance.
Many emerging tumor treatment strategies thus involve more temporally dynamic,
pulsatile delivery schedules [11-13] and even sequences of multiple anticancer
therapeutics [14-21].
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Polymeric hydrogels have shown the ability to release bioactive payloads in
response to externally applied stimuli such as changes in pH [22], light [23],
temperature [24], electric field [25], magnetic field [26-31], ultrasound [32-35]. These
stimuli-responsive polymeric hydrogel systems could thus provide the localized, ondemand, complex molecular deliveries needed to direct spatiotemporally complex
biological processes. Ultrasonically responsive hydrogels are of particular interest in
that ultrasound (US) has been extensively used in a wide variety of therapeutic
applications owing to its safety, relatively high spatiotemporal precision and ability to
penetrate tissues [36-38]. Ca2+ crosslinked hydrogels respond to ultrasound
stimulation reversibly (i.e., they can self-heal due to the calcium ions re-crosslinking
the network after US-stimulation) which gives enhanced release when stimulated and
minimal baseline release when not stimulated [33, 39]. However, repeated and/or toointense of US stimulus can irreversibly damage the hydrogel scaffold. This is
undesirable in that (i) alteration of the hydrogel structure can impact baseline release
kinetics and (ii) loss of hydrogel integrity could prohibit subsequent ultrasonically
triggered release events. Additionally, repeated and/or too-intense of US stimulus can
render sensitive payloads bio-inactive. While several previous studies have
demonstrated ultrasonically triggered release from hydrogels—with some systems
even demonstrating the ability to produce sequential release profiles by leveraging
multiple ultrasonically triggerable compartments [40-42]—it remains unclear (i) how
the intensity and duration of ultrasonic stimulation impacts release for a diverse range
of molecules, (ii) how the intensity and duration of ultrasonic stimulation impacts
temperature increase and hydrogel integrity, and (iii) if pulsatile and multi-payload
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delivery profiles can be produced through ultrasonic stimulation of bulk hydrogel
materials. The work presented here endeavored to elucidate these issues.
3.4.

Results

3.4.1. Impact of ultrasonic intensity and duration on molecular release from Ca+2
crosslinked hydrogels
To investigate how different ultrasonic exposures impacted release from calciumcrosslinked hydrogels, 1 wt% alginate hydrogels with 30 mM calcium crosslinker
were fabricated and pre-loaded with a variety of different molecules (dextrans of
various size and charge, chemotherapeutic agents, and different protein signaling
factors) (Figure 1a (i): hydrogels loaded with FITC-labeled dextran). This hydrogel
formulation was previously reported to be capable of ultrasonically triggered drug
delivery [33, 39, 42]. Immediately after making the hydrogels, they were cut into
small cylinders and were transferred to scintillation vials with 5 mL Dulbecco’s
phosphate buffered saline (DPBS) and subjected to ultrasound stimulation at various
amplitudes for various durations (Figure 1a (ii)-(vi)). Immediately following
ultrasonic stimulation, samples were collected to ascertain the amount of the
molecular release (Figure 1a (vii)) (see Materials and Methods for more details).
We hypothesized that the size and charge of molecules would have an impact on
ultrasonically stimulated release from these alginate hydrogels. To test this hypothesis,
we studied the release of four different model macromolecules (FITC dextrans) when
subjected to US stimulation of 0%, 20% and 40% amplitude for durations of 1 and 5
min. Two sizes were used: relatively small dextrans of 3-6 kDa and larger dextrans of
70 kDa. Additionally, to investigate the impact of charge, uncharged dextrans were
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used as well as DEAE-modified cationic dextrans. It was thought that the positively
charged side groups on the DEAE dextrans would electrostatically interact with the
negatively charged groups presented by the alginate hydrogel matrix, thus impacting
release.

Figure 1: Ultrasonic amplitude, ultrasonic duration, molecular size, and
molecular charge influence the amount of molecular release from Ca +2
crosslinked hydrogels. (a) FITC-Dextran-loaded Ca2+ crosslinked alginate hydrogel
fabrication: casting gel on a sigma-coated glass plate (i), cutting into 8-mm-diameter
cylindrical gels using a biopsy punch (ii), putting a gel in a scintillation vials with 5 ml
DPBS (iii), gels before, during, and after ultrasound stimulation (iv-vi), and 1 mL
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sample collection for quantifying molecular release (vii). (b) – (e) FITC-dextran
release vs. ultrasonic amplitude for gels exposed to 1-min (blue) and 5-min (red) of
ultrasonic stimulation. Asterisks (*) indicate levels of statistical differences for release
compared to controls (0% amplitude) unless otherwise specified with lines. N = 4.
Indeed, cationic dextrans released at levels generally lower (Figure 1d and 1e)
than their neutrally charged counterparts (Figure 1b and 1c). In some instances, the
size of the dextran impacted release as well. For example, ultrasonic stimulation did
not yield higher amounts of release than controls (0% amplitude) for hydrogels loaded
with larger cationic dextran, except when stimulated at 40% amplitude for 5 minutes
(Figure 1e). However, smaller cationic dextrans did release with statistical
significance at 20% amplitude for 5 minutes, 40% amplitude for 1 minute, and 40%
amplitude for 5 minutes (Figure 1d). For neutrally charged dextrans, size seemed to
particularly impact baseline, unstimulated release. For instance, higher amounts of
smaller neutral dextran released under 0% ultrasonic amplitude (Figure 1b, blue and
red bars at 0%) than larger neutral dextrans (Figure 1c, blue and red bars at 0%).
These results are consistent with the notion that larger, more electrostatically
interactive molecules exhibit less mobility in and through the negatively charged
hydrogel matrix and thus exit the matrix at reduced rates.
As expected, the amplitude and duration of ultrasonic stimulation also influenced
release. Generally, for increasing ultrasonic amplitudes, there was an upward trend in
the amount of molecular release (Figure 1b and 1c: both blue and red bars trended
upwards at increasing ultrasonic amplitudes). In fact, nearly all the drug contained in
each hydrogel (80.4 µg/gel) was released when stimulating neutral dextran-loaded
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hydrogels with 40% ultrasonic amplitude for 5 minutes (Figure 1b and 1c, red bars at
40%). However, this trend was less pronounced when examining the cationic dextrans.
The smaller cationic dextran maintained only a modest upward trend as ultrasonic
amplitude was increased (Figure 1d). This upward trend was not exhibited well for
the larger cationic dextran (Figure 1e). Thus, for larger molecules that exhibit the
opposite charge as the polymer matrix, there seems less ability to ultrasonically select
the amount of molecular release by stimulating at specific amplitudes and durations.
While the larger cationic dextran did release from the hydrogels with statistical
significance when stimulated at 40% ultrasonic amplitude for 5 minutes, these degrees
of ultrasonic stimulation may be disruptive to both the hydrogel structure and the
payload itself (see Section 2.2).
While the use of dextrans as model drugs was useful for understanding general
trends in how molecular weight and charge impacted ultrasonically triggered delivery,
we wanted to perform experiments characterizing the release of actual therapeutic
agents. Therefore, we investigated the release of small molecular weight
chemotherapeutics (mitoxantrone, irinotecan, and 5-fluorouracil) from these hydrogels
under the ultrasonic stimulus. Note that when using different chemotherapeutic agents,
different amounts of agent needed to be loaded in the hydrogels in order for the
amount released to be detectable and quantifiable via absorbance spectroscopy (40.2
µg/gel, 201.1 µg/gel, and 80.4 µg/gel of chemotherapeutic for mitoxantrone,
irinotecan, and 5FU respectively). Thus, these data are plotted as percent release on
their y-axis rather than the amount released in weight for easier comparisons. As with
the model dextrans, stronger US amplitudes generally resulted in a higher degree of

54

drug release (Figure 2, bars trend upwards for increasing amounts of ultrasonic
amplitude). Also, increasing the duration of ultrasonic stimulation increased the
amount of release (Figure 2, red bars are generally higher than blue bars at the same
ultrasonic amplitude).

Figure 2: The amplitude and duration of ultrasonic stimulation impact the
amount of chemotherapeutic released. Release vs. ultrasonic amplitude for
mitoxantrone (a), irinotecan (b), and 5-fluorouracil (c). Asterisks (*) indicate
statistically significant release compared to controls (0% amplitude) unless otherwise
specified with lines. N = 4.
The relative size and charge of these chemotherapeutics likely impacted release
characteristics to some degree, though some inconsistencies were observed. Though
all three-chemotherapeutics tested here were relatively small molecules, they did
exhibit different charges: mitoxantrone (444.5 Da, +2 charge), irinotecan (586.7 Da,
+1 charge), and 5FU (130.1 Da, neutral charge). Irinotecan diffused out of the gels at
higher levels than mitoxantrone (Figures 2a and 2b: red and blue bars a 0% are higher
for irinotecan than mitoxantrone). This seemed reasonable in that irinotecan had a
lower positive charge density and would have a lower electrostatic affinity to the
negatively charged alginate matrix. However, 5FU (which is neutral and the smallest
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chemotherapeutic examined here) did not diffuse out of the gels at lower amounts than
irinotecan as initially expected (Figure 2b and 2c: bars at 0% US amplitude were, in
fact, lower for 5FU than irinotecan). Note, however, that release kinetics are also
based on parameters such as polarity. In fact, 5FU is polar and water-soluble (~1 g/L)
whereas irinotecan is less water-soluble (~0.1 g/L). Thus, 5FU may present more
opportunities to hydrogen-bond with alginate (which presents an abundance of
electronegative groups) compared to the less polar irinotecan. But, for all three
chemotherapeutics, application of ultrasound greatly enhanced release. 75% - 90% of
chemotherapeutic could be released when stimulated at 40% ultrasonic amplitude for 5
minutes (though with the caveat that this type of ultrasonic stimulation may be
disruptive to the gel and possibly even the drug molecule itself).

Figure 3: The amplitude and duration of ultrasonic stimulation impact the
amount of signaling factor released. Release vs. ultrasonic intensity for VEGF (a)
and PDGF (b). Asterisks (*) indicate statistically significant release compared to
controls (0% amplitude) unless otherwise specified with lines. N = 4.
To examine how ultrasonic stimulation impacted signaling factor release,
calcium-crosslinked alginate gels were loaded with 6100 pg/gel of vascular
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endothelial growth factor (VEGF, a pro-angiogenic factor) and platelet-derived growth
factor (PDGF, a pro-maturation factor) and stimulated at various ultrasonic amplitudes
for different amounts of time. Despite being loaded with the same amount of protein,
VEGF generally released in higher amounts than PDGF (Figure 3, comparing parts a
to b). This is likely due to VEGF having a lower affinity to the alginate contained in
the hydrogel’s matrix compared to PDGF’s alginate affinity. As was seen with
dextrans and chemotherapeutics, longer ultrasonic durations and stronger amplitudes
resulted in higher levels of release (Figure 3, upward trends at higher amplitudes and
red bars being higher than blue bars at the same amplitude).
3.4.2. Erosion and heating of scaffold due to ultrasound stimulation
While the data described in the previous section underscores the ability to
ultrasonically regulate molecular release, application of ultrasonic stimulation can
potentially irreversibly damage the hydrogel structure (prohibiting subsequent
deliveries from the hydrogel) and/or reduce the bioactivity of sensitive therapeutic
payloads (like protein signaling factors due to thermally induced conformational
alterations). To investigate the range of ultrasonic stimulations that do not overly
erode or heat the hydrogel structure, experiments were conducted that quantified the
degree of hydrogel erosion and rise in temperature when exposed to different
amplitudes and durations of ultrasound. As expected, with higher ultrasonic
amplitudes and longer durations of exposure, hydrogel erosion was more pronounced
(Figure 4a: photos of gels under different US conditions that were loaded with blue
mitoxantrone). Quantifications of erosion (percent weight loss before/after ultrasound)
revealed that the maximum US exposure (40% amplitude for 5 minutes) significantly
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eroded these gels (Figure 4b). However, all other US conditions yielded erosions
lower than 50%. In terms of gel heating, all ultrasonic stimulations resulted in heating,
as expected. However, it was desirable to keep temperature increases to under 80C
(i.e., as to not increase temperatures from body temperature (370C) to temperatures
that may impact protein conformation (450C)). Indeed, both the 1-minute at 20% US
amplitude and 5-minute at 20% US amplitude conditions heated samples less than 80C
(Figure 4c). When taking both gel erosion and heating into account, the 1-minute 20%
of US exposures appeared to be the safest to use. However, these 1-minute, 20% US
amplitude exposures did not yield statistically significant enhancements in release for
cationic dextrans (Figures 1d and 1e, blue bars at 20%), mitoxantrone (Figure 2a,
blue bar at 20%), or VEGF and PDGF (Figure 3, blue bars at 20%).

Figure 4: Ultrasound erodes and heats the gels in manners that are dependent on
the intensity and duration of the applied ultrasound. (a) Photographs of
mitoxantrone-loaded hydrogels after exposure to the US at the indicated amplitudes
and durations. (b) Percent weight loss vs US intensity for gels stimulated for 1 minute
(light blue) and 5 minutes (light purple). (c) Temperature elevation vs US intensity for
gels stimulated for 1 minute (yellow) and 5 minutes (orange). Asterisks (*) indicate
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statistically significant differences compared to controls (0% amplitude) unless
otherwise specified with lines. N = 4.
3.4.3. Triggered release delivery by pulsing the ultrasound stimulation
Even though 1-minute ultrasound exposures at 20% amplitude did not statistically
enhance releases for a many of molecules tested here, we hypothesized that repeated
1-min, 20% US exposures could enhance release while helping to preserve hydrogel
structure and maintain relatively low temperatures. That is, the mechanism of
ultrasonic release from these calcium-crosslinked alginate hydrogels is thought to be
due to the displacement of calcium crosslinks (due to ultrasonically driven cavitation
within the matrix) [33, 39, 41]. This displacement allows the matrix to unravel, and in
the process, liberate drugs trapped within the matrix. If ultrasonically stimulated
mildly enough, the matrix may remain relatively intact with enough free calcium
crosslinkers present to re-crosslink the matrix upon termination of the ultrasonic
stimulus (though some drug may be liberated from the matrix during stimulation). If
the ultrasonic stimulation is of sufficient duration and intensity, the calcium
crosslinked, and the alginate polymer may become so dispersed that the matrix is not
able to re-crosslink. So, if a gel is (i) initially stimulated with the US that does not
overly disrupt the matrix but produces some drug release, then (ii) left to recover with
the US is turned off, and then (iii) subsequently stimulated with US and allowed to
recover, these pauses in ultrasonic stimulation may enable appreciable amounts of
accumulated release while providing time for the matrix to recover and for heat to
dissipate between subsequent ultrasonic stimulations.
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To test this hypothesis, we exposed calcium-crosslinked alginate gels to 1-minute
US pulses at 20% amplitude in pulse trains with varying pulse numbers over a 1-hour
period. Specifically, gels were exposed to controls (no pulses), one 1-min pulse, two
1-min pulses, three 1-min pulses, and four 1-min pulses (Figure 5a, moving left to
right).

Figure 5: Pulsed ultrasound can enhance drug delivery while helping to control
gel erosion and heating. (a) Photos of hydrogels (bottom row) after exposure to the
illustrated ultrasonic pulse trains (top row). (b) Percent weight loss of hydrogels vs.
pulse number. (c) Temperature rise vs. pulse number. (d) Mitoxantrone release vs.
pulse number. Asterisks (*) indicate statistically significant differences when
compared controls unless otherwise specified with lines. N = 4.
Additionally, gels were exposed to one 4-min pulse (Figure 5a, rightmost
illustration) which is equivalent to four 1-min pulses with no delay time between
them. This was done to directly compare the same total exposure of ultrasonic
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stimulation with and without pauses (i.e. pulsed ultrasound vs. continuous). While
increasing the number of ultrasonic pulses slightly increased the degree of erosion
(Figure 5b: increasing values for 1, 2, 3, and 4 1-min pulses, though the 3 and 4 pulse
conditions were statistically indifferent), temperature elevation did not appreciably
increase for higher pulse numbers (Figure 5c: similar values for 1, 2, 3, and 4 1-min
pulses). And, the amount of drug released did increase for increasing pulse numbers
(Figure 5d: increasing values for 1, 2, 3, and 4 1-min pulses). Thus, increasing the
number of ultrasonic pulses may provide a means to increase drug release while
helping to minimize temperature increase and, to some extent, help maintain gel
structure (compared to increasing the amplitude or duration of the US signal, which
was shown to dramatically increase heating and gel erosion (Figure 4b and 4c)).
Also, of note was that one continuous 4-minute pulse eroded and heated the gel
much more than 4 individual 1-minute pulses separated by 14 minutes (Figures 5a
and 5b: comparing 1,4-min bars to 4, 4-min bars). While the highly eroded gel
naturally yielded a higher degree of drug release (Figure 5c, comparing 1,4-min bars
to 4, 4-min bars), these results suggest that pausing between shorter US pulses can
help maintain the structure and temperature of the gel while still producing statistically
significant amounts of drug release.
3.4.4. Ultrasonically generating pulsatile temporal delivery profiles
As discussed in the introduction, many emerging drug delivery strategies involve
generating localized delivery profiles that are more temporally complex. For example,
there is growing evidence that pulsatile chemotherapeutic delivery profiles are more
effective in destroying tumor cells than sustained deliveries [11, 19, 33, 43]. Because
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of this potential, we aimed to demonstrate that ultrasonic stimulation could be used to
generate pulsatile delivery profiles from these gels by periodically turning on and off
the ultrasonic signal. To mimic a pulsatile mitoxantrone delivery profile that was
previously demonstrated to enhance melanoma cell destruction [43], we exposed
mitoxantrone-loaded, calcium-crosslinked alginate hydrogels to a 1-hour period of
pulsed US stimulation one time a day for 3 days. Specifically, for a 1-hour period each
day (for 3 days total), gels were stimulated with various US pulse trains composed of
1-minute pulses at 20% amplitude: (i) 0 pulses (control), (ii) one 1-minute pulse (and
59 minutes of no stimulation), (iii) two 1-minute pulses (with 29 minutes of no
stimulation following each pulse), and (iv) three 1-minute pulses (with 19 minutes of
no stimulation following each pulse).

Figure 6: Ultrasound can be used to generate pulsatile chemotherapeutic delivery
profiles over a 3-day period, though gel structure is not maintained, and delivery
rates change vs. time. (a) Photos of hydrogels immediately after ultrasonic exposures
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on the indicated days. (b-d) The rate of mitoxantrone release vs time when stimulated
with pulsed ultrasound for 1 hour each day for control and one 1-min pulse (b), two 1min pulses (c), and thee 1-min pulses (d). Asterisks (*) indicate the degree of
statistical differences relative to controls. n.s. indicates that no statistical significance
was found compared to controls. N = 4.
Photographs were taken immediately following each 1-hour stimulation period to
assess the relative degree of gel erosion (Figure 6a). As expected, US exposure
regiments that involved a higher number of pulses generally resulted in higher degrees
of gel erosion. For US exposures of two and three 1-minute US exposures, gels
exhibited high degrees of erosion by the 3rd day of the experiment (Figure 6a,
rightmost column, bottom two rows: gels began to fragment). While exposures to
single 1-minute US pulses allowed the gels to remain relatively intact (Figure 6a,
rightmost column, 2nd from top row), these mild ultrasonic stimulations did not
produce pulsed mitoxantrone release rates that were statistically higher than controls
(Figure 6b, red and black curves are statistically similar). The two and three 1-minute
pulsed US exposures did yield statistically significant mitoxantrone release rates
during these 1-hour “on” periods (Figures 6c and 6d) but did so in an inconsistent
manner vs. time. That is, mitoxantrone release rates during 1-hour “on” periods tended
to increase over time, particularly on the final day of the experiments (Figure 6c and
6d: the pulse heights from 48-49 hours were higher than from 0-1 and 24-25 hours).
We attributed this to the gel being more highly eroded from repeated ultrasonic
exposures, having more surface area by day 3, and possibly being more fragile.
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Nonetheless, statistically significant pulsatile delivery rates were achieved, and the
gels were not completely annihilated after these 3-day experiments.
To achieve more consistent pulsatile mitoxantrone delivery rates during
subsequent “on” periods and to help maintain gel structure, we explored the idea of
modifying US exposures vs. time. Specifically, we reduced the number of US pulses
used during the 1-hour US exposure period on day 2. That is, we used 3, 1-minute
pulses on day 1 (from 0-1 hours), and then reduced the US pulse number to 2, 1minute pulses on days 2 and 3 (from 24-25 hours and from 48-49 hours). This strategy
resulted in more mild gel erosion over time upon visual inspection (Figure 7a, bottom
row) and provided more uniform mitoxantrone pulse rates during 1-hour “on” periods
on subsequent days (Figure. 7b, pulse heights of the blue curve are of similar heights
at times 0, 24, and 48 hours).

Figure 7: Pulsatile delivery profiles with consistent release rates vs. time can be
achieved by altering the US pulse number over time. (a) Photos of hydrogels
immediately after ultrasonic exposure on each day for control gels and those exposed
to the indicated pulsed US regiment. (b) Release rate vs. time when stimulated with 3,

64

1-min; 2, 1-min; and 2, 1-min ultrasound pulses on day 1, 2, and 3, respectively.
Asterisks (*) indicates levels of statistical differences relative to controls. N = 4.
3.4.5. Sequential 5-fluorouracil and irinotecan delivery on melanoma cells in vitro
Some treatment strategies involve the sequential delivery of two or more
therapeutics. For example, sequential delivery of 5FU and irinotecan is commonly
used for treating colorectal cancer, though there is some debate as to which therapeutic
should be delivered first: 5FU followed by irinotecan vs. irinotecan followed by 5FU
[17-18, 21]. Though particular sequences may be used to optimize therapeutic
outcome, other parameters likely impact outcome as well: the duration of each
therapeutic delivery, the temporal profile of each therapeutic delivery, the relative
dose of each therapeutic, the spacing between each delivery, etc. For example, we
conducted in vitro experiments on melanoma cells by exposing them to different
delivery schedules involving both 5FU and irinotecan. B16F10 mouse melanoma cells
were plated, allowed to grow for 36 hours, and then exposed to different delivery
schedules of 5FU and irinotecan for 36 hours (Figure 8a, schedules s1 – s4). B16F10
populations were monitored in real time using an xCELLigence system (which uses
the electrical impedance of a well-plates surface to quantify cell population vs. time).
xCELLigence data from these experiments are included as cell index (a measure of
cell population) vs. time in Figure 8b. For the four delivery schedules used here (s1 –
s4), all resulted in statistically similar B16f10 populations except for schedule s3
(Figure 8b, s3 purple curve resulted in statistically smaller populations at +36 hours).
So, for these particular 5FU and irinotecan doses, durations, and timings on this
particular cell type in vitro, schedule s3 (5FU followed by irinotecan) was most
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effective in reducing melanoma cell populations. Critically, it is unclear what
sequence would be optimal when testing a more diverse array of drug types, timings,
doses, and sequences on different types of cancers in vivo. Therefore, material systems
are urgently needed where these types of parameters can be readily controlled and
modified from experiment to experiment. Ultrasonically responsive hydrogels could
provide a material system for performing such optimizations in vivo if they can be
tailored to generate multi-therapeutic, sequential delivery profiles.

Figure 8: 5-fluorouracil and irinotecan delivery sequence had an impact on
melanoma cell survival. (a) A timeline describing the in vitro cytotoxicity experiment
where B16F10 mouse melanoma cells were seeded and allowed to grow for 36 hours
before treatment and exposed to several treatment schedules s1-s4 for 36 hours. (b)
Normalized cell index (B16-F10 cell population) vs. time when exposed to s1 (red
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curve), s2 (blue curve), s3 (purple curve, blue marker), s4 (purple curve, red marker).
** indicates a statistically significant difference with p < 0.01. N = 4.
3.4.6. Generation of the sequential 5-fluorouracil and irinotecan deliveries
To demonstrate the ability to produce sequential delivery profiles from these
ultrasonically responsive hydrogels, we aimed to mimic the delivery profile which
reduced melanoma cell populations most efficiently in the above-described studies:
schedule s3 (initial 5FU delivery followed by irinotecan delivery starting at 18 hours).
So, one criterion of our design demanded that 5FU exit the gels rapidly at early time
points. While 5FU did not diffusively release as much as irinotecan (comparing
Figures 2b and 2c at 0% US amplitude), a non-trivial amount of 5FU still did released
when no ultrasonic stimulation was applied (Figure 2c, ~10% release in 1 to 5
minutes). We believed that, over the course of 18 hours, this amount of release could
be therapeutically relevant. Thus, our strategy was to design the gel to initially release
5FU via diffusion with no ultrasonic stimulation and then ultrasonically trigger
irinotecan release at 18 hours. Additionally, the initial release of 5FU could be further
enhanced by the method of loading 5FU into the gel. That is, instead of incorporating
5FU into the matrix during gel fabrication, 5FU could be loaded by soaking the gel in
concentrated 5FU to the gel after gel fabrication. This would potentially limit how
well 5FU incorporated into the gel and help it release more readily from the matrix.
To achieve delayed, ultrasonically triggered irinotecan delivery, it was desirable
to have the gel release as little irinotecan as possible when no ultrasound was applied
for the first 18 hours and then release as much as possible when ultrasonically
stimulated (at 18 hours). However, examination of Figure 2b reveals that irinotecan
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releases at high rates, even when not ultrasonically stimulated (> 40% release in 5
minutes = 80 mg in 5 minutes = 16 mg/min). To enhance unstimulated irinotecan
retention, we pursued two strategies. First, we believed that reducing the hydrogel’s
mesh size (by increasing the polymer and crosslinker concentrations from 1.0 wt%
alginate with 30 mM Ca2+ to 1.6 wt% alginate w/ith 50 mM Ca2+) would serve to
better entrap and impede the release of irinotecan. This, of course, could also lead to
lower amounts of release when ultrasonically stimulated. However, ultrasonically
stimulated delivery of irinotecan could be very efficient (Figure 2b, 40% US
amplitude for 5 min results in 90-100% release). So, we hoped that ultrasonic
stimulation would still produce strong amounts of irinotecan release even with higher
polymer and crosslinker concentrations. Second, we believed that rinsing the gels
could help reduce the amount of diffusive irinotecan release at early time points. The
studies presented in Figure 2 were performed immediately after gel formation and did
not include a rinsing step. If they were rinsed, some of the less well-incorporated
irinotecan could be removed, thereby reducing initial, diffusive release.

Figure 9: Ultrasonically responsive gels can be used to generate a triggered
release of irinotecan after an initial burst release of 5-fluorouracil. (a) Cumulative
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release of 5-fluorouracil (blue) and irinotecan (red) vs time when ultrasonically
stimulated for 2-minutes at 40% US amplitude at 18 hours. Control gels (black) were
not subjected to ultrasonic stimulation at 18 hours. (b) The 18-hour average rate of 5fluorouracil and irinotecan release vs. time for the same conditions presented in part
(a). Asterisk (*) indicates levels of statistical differences relative to controls. N = 4.
Taking this all together, we produced 1.6 wt% alginate, 50 mM calciumcrosslinked gels (60% polymer and crosslinker) that were loaded with 200 mg/gel of
irinotecan and 0 mg of 5FU. Gels were rinsed for 5 minutes in 5 mL of DPBS to
remove excess irinotecan that did not incorporate well into the hydrogel matrix. Then,
gels were soaked in 100 mL of concentrated 5FU (2 mg/mL) for 30 minutes to load
the gels with 5FU in a manner that would be conducive to rapid, burst release. When
placed in experimental media at time 0, indeed, gels released 5FU rapidly with low
levels of irinotecan release (Figure 9a: 5FU curve (blue) rises to ~ 90 mg in the first 2
hours whereas the irinotecan curve (red) does not rise to detectable levels). For the 18
hours prior to ultrasonic stimulation, 5FU reached ~100 mg of cumulative release
whereas irinotecan reached only ~10 mg (Figure 9a: values of blue and red curves at
18 hours, respectively). Immediately after being stimulated with an ultrasonic signal at
40% US amplitude for 2 minutes, irinotecan released reached over 25 mg of
cumulative release (Figure 9a, jump in the red curve just after 18 hours). However,
because the gel still had 5FU loaded in it, 5FU levels also increased in response to
ultrasonic stimulation (Figure 9a, jump in a blue curve just after 18 hours). For the
remaining 18 hours of the experiments, very little changes in 5FU and irinotecan
release were observed (Figure 9a: flatline curves from just after US stimulation to 36
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hours). When looking at time-average release rates for the 18 hours prior to and
following the US, as designed, release rates of 5FU were higher before the US and fell
to lower levels after US (Figure 9b, the blue curve is at higher values before 18 hours).
And, irinotecan release rates were lower before the US and increased after the US
(Figure 9b: red curve is at higher values after ultrasound).
3.5.

Discussion
The ultrasonically responsive Ca2+ crosslinked hydrogels explored here were

capable of producing various delivery profiles that may provide benefits, particularly
in cancer treatment strategies. The pulsatile release profiles demonstrated here (one, 1hour “on” period of enhanced mitoxantrone delivery per day for 3 days) were
demonstrated to reduce melanoma cell populations more effectively than the more
constant delivery profiles provided by traditional hydrogel materials [33, 43]. It is
thought that pulsatile deliveries can also help combat adaptive resistance in tumors
[11-13, 19]. Critically, the specific pulsatile delivery parameters (i.e., pulse height
(dose), pulse width (duration), duty cycle (the relatively time when the delivery is high
vs. low), and pulse number (how many periods of enhanced delivery per day)) that
lead to optimized tumor cell destruction likely depend on the specific therapeutics
used, the type of tumor, and other patient specifics. Though this presents a wide
parametric space for optimization, ultrasonically responsive gels such as those
presented here could help streamline these optimizations. That is, delivery parameters
such as pulse height, width, and duty cycle can be flexibly regulated by altering the
timing, duration, amplitude, and pulse number of the ultrasonic signal. The studies
presented here have uncovered some additional considerations moving forward.
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Namely, that undesirable temperature increases and gel erosion occur at longer and
higher-amplitude ultrasonic stimulations and that erosion can impact release kinetics
vs. time (higher release rates vs. time). However, we presented strategies for dealing
with these issues (i.e., by pulsing the ultrasonic signal itself and reducing ultrasonic
stimulations vs. time).
While the pulsatile deliver profiles generated in these studies (Figure 7b) are very
similar to those demonstrated to improve melanoma cell destruction [43], it remains
unclear with what level of flexibility ultrasonically responsive gels systems can
produce a diverse range of pulsatile delivery profiles while preserving gel integrity
and temperature. For example, studies still need to be performed to demonstrate how
many subsequent pulses can be generated before the gel is either depleted of drug or
erodes to the point of disused. The range of delivery rates achievable during ultrasonic
stimulation has also not been identified. While we believe that increasing US
parameters such as amplitude, duration, and US pulse number will increase the rates of
delivery, increasing these parameters also generates more heat and erodes the gels (as
demonstrated here). Note, that while generation and heat and gel erosion can limit
subsequent releases and render some more sensitive payloads bio-inactive, ultrasonic
stimulation can have a complimentary effect on damaging tumors, as demonstrated
previously by Heubsch et al. [33]. The studies conducted here have shown that 8 to 10
µg/min mitoxantrone pulses can be achieved while preserving gel structures for 3
days, but we have not explored pulse numbers beyond 3, ultrasonic amplitudes and
durations beyond 20% and 1-minute, or the pulsatile delivery of other anticancer
payloads. Some fine-tuning can likely be achieved. Nonetheless, we believe these
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studies underscore the potential of these ultrasonically responsive gels to provide
pulsatile delivery strategies and reinforce the need for continued exploration of their
potential.
In addition to pulsatile anticancer deliveries, these ultrasonically responsive gels
were demonstrated to produce a particular sequence of 5FU and irinotecan deliveries
that were shown to reduce melanoma cells populations in vitro (i.e., 18 hours of
heightened 5FU delivery followed by 18 hours of heightened irinotecan delivery)
(Figures 8 and 9). While a specific drug-loading strategy was used to attain this
specific sequence (i.e., irinotecan was loaded during gel fabrication and rinsed for
enhanced retention whereas 5FU was loaded just prior to the start of the experiment
for enhanced burst release), similar strategies can be employed for achieving different
sequences. For example, if—as some believe it to be more beneficial [17, 21, 44]—a
sequence of irinotecan followed by 5FU is desired, then 5FU can be incorporated
during gel formation and irinotecan can be added just prior to experimentation. Future
work on gel system demonstrated here includes optimizing parameters for achieving
specific delivery rates at different times. For example, characterizations are needed to
determine how hydrogel formulation (polymer and crosslinker concentrations), the
ultrasonic stimulation parameters (US amplitude, US pulse width, US pulse number
and delay between pulses), and the manner of loading various payloads impact the
delivery rates of baseline, unstimulated irinotecan release rates and ultrasonically
triggered irinotecan release rates. Additionally, future work needs to explore how
changing these parameters can be used to control the timing of the sequence release.
For instance, in these studies, delayed irinotecan release occurred at 18 hours. Being
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able to flexibly control this time point will be critical to optimizing therapies.
Ultrasonically responsive gel systems may provide unique advantages for optimizing
the timing of deliveries in that trigged deliveries directly correspond to the timing of
ultrasonic signal application. Finally, some cancer treatment strategies utilize
sequences of different therapeutics [14-16]. Continued exploration of these
ultrasonically responsive gels is needed to determine if they are suitable for
coordinating sequential delivery of other therapeutic agents in cancer treatment and
beyond.
Finally, while these hydrogels demonstrated promise for producing sequential
deliveries in cancer treatments, they may also be of use in treating injuries and
diseases for which sequential biological process must be controlled. The ability to
generate sequential delivery profiles would be of great utility in tissue engineering
applications, where sequences of biological events (such as recruitment, proliferation,
and differentiation) can be directed through sequential delivery of recruitment,
proliferation, and differentiation signaling factors [3, 6-9]. In addition to sequencing
these factors (to establish tissue-specific cell types at the site of regeneration),
vascularizing regenerated tissue is also critical. Generation of new vasculature also
involves an important sequence of biological events: (i) generation of angiogenic
sprouts from nearby, existing vasculature (which can be induced by projecting a proangiogenic signal gradients—such as VEGF—emanating away from the regeneration
site) and (ii) maturation of the newly established network of angiogenic sprouts into
larger, blood-perfusing vessels (which can directed through localized deliveries of promaturation factors—such as PDGF) [1-2]. Thus, calcium-crosslinked alginate gels
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may enable the establishment of VEGF gradients through diffusive release of VEGF
followed by delayed, ultrasonically triggered release of PDGF. This may help
optimize deliver strategies for regenerating vasculature in tissue engineering
applications. In fact, we demonstrated VEGF releases in modest amounts under no
ultrasonic stimulation (Figure 3a, 200 pg in 5 minutes at 0% US amplitude). This may
aid in generating initial burst release of VEGF. PDGF tends to release in lower
quantities when not ultrasonically stimulated (Figure 3b, ~50 pg in 5 minutes at 0%
US amplitude). However, when ultrasonically stimulated, PDGF release can be
substantially enhanced (for example, Figure 3b: ~200 pg in 1 minute at 40% US
amplitude). These attributes may help retain PDGF when not ultrasonically stimulated
and enable its triggered release when stimulated.
3.6.

Materials and Methods

3.6.1 Materials
B16F10 mouse melanoma cancer cells were purchased from American Type
Culture Collection (ATCC, Manassas, VA). Sodium alginate (Protanal LF20/40) of
high molecular weight (~ 250 kDa) was donated by FMC BioPolymers (Philadelphia,
PA). Trypan Blue, Dulbecco’s modified eagle’s medium (DMEM), bovine serum
albumin (BSA), fetal bovine serum (FBS), penicillin-streptomycin, and trypsin-EDTA
solutions, morpholineethanesulfonic acid (MES) hydrate, Dulbecco’s phosphate
buffered saline (DPBS), Sigmacote, activated charcoal, calcium sulfate dihydrate,
irinotecan hydrochloride, 5-fluorouracil, mitoxantrone hydrochloride, fluorescein
isothiocyanate (FITC) dextran (3-6 kDa and 70 kDa), fluorescein isothiocyanate
diethylaminoethyl (FITC-DEAE) dextran (3-6 kDa and 70 kDa) and rhodamine
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dextran (10 kDa) were all purchased from Sigma-Aldrich (St. Louis, MO). Vascular
endothelial growth factor (VEGF), Platelet-derived growth factor (PDGF), Bone
morphogenic protein-2 (BMP-2), stromal cell-derived factor-1 alpha (SDF-1α),
VEGF, PDGF, BMP-1, and SDF-1α DuoSet ELISA kits were purchased from R&D
Systems, Inc (Minneapolis, MN). 16-well xCELLigence e-plates were purchased from
ACEA Biosciences, Inc. (San Diego, CA).
3.6.2 Calcium Crosslinked Hydrogel Fabrication
To make ultrasonically responsive hydrogels, alginate was purified through
dialysis (3500 MW cut off, Spectrum Laboratories, Compton, CA), activated charcoal
treatment, filtration, and lyophilization. In a previously described manner [33],
alginate was dissolved in MES buffer (pH = 6.5) to make a 2.5 wt % alginate solution.
2 mL of 2.5 wt % alginate solution was mixed with 2 mL solution of a molecules of
interest (drug, protein, or dextran dissolved in MES buffer). This 4 mL solution of
alginate and “drug” was quickly mixed with 1 mL of 21 mg/mL CaSO4 in water slurry
by linking two 5 mL syringes (Becton, Dickinson and Company, Franklin Lakes, NJ)
together with a LuerLock Connector (W. W. Granger Inc., Lake Forest, IL) and
rapidly transferring the mixture back and forth between syringes. Hydrogels were cast
by quickly discharging the contents of the LuerLock syringes on glass plates and
immediately placing a second glass plate on top of the gel mixture with 2-mm spacers
in between the two plates. After gelation (30 min), individual 8 mm diameter
cylindrical gels were cut using a biopsy punch. The resulting Ca2+ crosslinked 1 wt %
alginate, 30 mM calcium-crosslinked hydrogels had 8 x 2 mm cylindrical structures.
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3.6.3 Release Studies
The Ca2+ crosslinked hydrogels were loaded with a drug, protein or dextran
during the gel fabrication process as described above. Immediately after cutting the
hydrogels, they were transferred to 5 mL of DPBS contained in Sigmacote-treated
scintillation vials (to prevent molecular adsorption to the walls of the vial) and
simulated with a 20 kHz ultrasonicator using a standard 1/8” microtip (5.4” L × 0.5”
dia, titanium alloy, 0.25 lbs.) sonication probe (QSONICA, Newtown, CT) at various
ultrasonic amplitudes (%) and durations: amplitudes ranging from 0% to 40% for
durations between 1 and 5 minutes. Previous analyses revealed that 20% US
amplitudes corresponded to ultrasonic powers of 0.714 ± 0.02 W and 40% US
amplitudes corresponded to 2.09 ± 0.05 W. Immediately after stimulation, 1 mL
samples were taken from the scintillation vials for later analysis to quantify the
amount of molecular release. In time-course experiments where multiple samples were
acquired to plot release vs. time, 1 mL samples were removed from the vials and saved
for later analysis, and the remaining 4 mL was removed and discarded. A fresh 5 mL
of DPBS was added for the next time point. The concentration of FITC-dextran
release was quantified using fluorescence ex/em at 495 nm and 525 nm in a BioTek
Cytation3 microplate reader against a standard curve. The concentrations of
mitoxantrone, 5-fluorouracil and irinotecan release samples were quantified by
measuring optical absorbance at 610 nm, 350 nm, and 370 nm, respectively, on the
plate reader against a standard curve. ELISA was used to measure the concentration of
signaling factor release (VEGF and PDGF).
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3.6.4 Sequential Release Studies
1.6 wt% alginate hydrogels were crosslinked with 50 mM CaSO4 solutions and
loaded with irinotecan at 100 µg/gel using methods described in the previous sections.
Immediately after cutting the 8-mm-diamter cylindrical hydrogels, they were rinsed
for 5 min with 5 mL of DPBS to remove unincorporated irinotecan. Then each gel was
soaked with 100 µL of 2 mg/mL 5FU for 30 min to load then with 5FU in a manner
that would facilitate rapid 5FU release. After soaking, gels were transferred into new
scintillation vials. The experiments began when 5 mL of DPBS was added to the
scintillation vials. At 18 hours, gels were subjected to ultrasound stimulation at 40%
US amplitude for 2 min. Samples were collected at various time points and analyzed
for irinotecan and 5FU release using a plate reader as described in the previous
section.
3.6.5 Cell Culture and Maintenance
B16-F10 mouse melanoma cells were cultured in DMEM with 10% FBS and 1%
penicillin-streptomycin at 37ºC in 5% CO2. B16-F10s were routinely split to avoid
confluence over 70%, roughly every other day, by trypsinizing (5 min with 0.25% w/v
trypsin and 0.5 mM EDTA), collecting, centrifuging, washing, and re-seeding on 75
cm2 flasks.
3.6.6 In Vitro Melanoma Cell Survival Studies
The effect of sequential 5-fluorouracil and irinotecan exposure was compared
with delivering 5-fluorouracil (5FU) and irinotecan to B16F10 mouse melanoma cells
in vitro on an xCELLigence real-time cell index system. B16F10s were seeded at 500
cells per cm2 on 16-well xCELLigence e-plates and allowed to grow in DMEM for 36
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h. Then, B16F10s were exposed to various combinations of 5-fluorouracil and
irinotecan (Figure 8a, schedules S1 to S4) for 36 hours. For delivery schedules that
involved changing the drug vs. time (i.e., schedules S3 and S4 for sequential deliveries
of 5FU and irinotecan), cells were rinsed 3 times with fresh DMEM immediately after
removing the first drug (at the 18-hour mark) as to remove any residual drug before
adding the other drug. Real-time cell index data (indicating cell population levels)
were collected using xCELLigence software for analysis and plotting. Cell index
values were normalized and set to 1 at time 0 when treatment began. Each condition
S1 through S4 was repeated in 4 separate wells (N = 4) to compute means and
standard deviation. Note that a control condition is not included (i.e., one where no
chemotherapeutic is delivered). This was not included because cell index values
saturated the xCELLigence system when no anticancer agent was present to impede
B16F10 growth (i.e., B16F10s reached confluency during the experiment, saturating
the cell index signal).
3.6.7 Data Representation and Statistical Analysis
All quantitative data presented here are represented by means ± standard
deviation. For all statistical analyses, one-way Analysis of Variance (ANOVA) was
used with Tukey’s post-hoc tests for multiple comparisons (using Kaleidagraph
software, version 4.5.2) with p-values of less than 0.05 being our benchmark for
statistical significance. *, **, ***, and **** indicates statistical significance of p <
0.05, 0.01, 0.001, and 0.0001 respectively. n.s. indicates no statistical significance. (p
> 0.05).
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3.7.

Conclusions
The work presented here first characterized how different molecular payloads

were released when subjected to ultrasonic signals of various amplitudes and
durations. While stronger amplitudes and longer durations enhanced molecular
delivery to higher degrees, they also eroded the hydrogels and increased hydrogel
temperatures, often to ranges that could damage sensitive protein payloads.
Ultrasonically induced gel erosion also altered the release characteristics (generating
higher amounts of release vs. time) and sometimes prohibited subsequent ultrasonic
triggering of molecular release (i.e., when the gels because completely eroded).
Erosion and heating could be minimized by using lower ultrasonic amplitudes for
shorter durations, but these stimulations did not yield statistically significant payload
deliveries. This work went on to demonstrate that pulsing of the ultrasonic signal (i.e.,
by only stimulating in short, 1-minute ultrasonic bursts, and pausing between bursts)
could be used to reduce erosion and temperature increase while still generating
statistically significant amounts of payload release. This work also demonstrated that
both pulsatile and sequential cancer therapeutic delivery profiles could be achieved.
Pulsatile deliveries (i.e., 1-hour periods of enhanced delivery rates of ~8 µg/hr per day
for 3 days) were generated by pulsing ultrasonic stimulations for short periods of time
over the course of 3-day experiments. Of note was that the pulsatile mitoxantrone
delivery profiles achieved here were previously shown to improve the destruction of
melanoma cells in vitro [43]. In vitro experiments conducted here demonstrated that a
sequential delivery profile of 5FU (for 18 hours) followed by irinotecan (at 18 hours)
reduced melanoma cell populations compared to irinotecan delivery alone, 5FU
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delivery alone, and a sequence of irinotecan followed by 5FU. These calciumcrosslinked alginate gels were demonstrated to reproduce a similar sequential profile
of initial 5FU deliveries followed by ultrasonically triggered delivery of irinotecan at
18 hours. In sum, these characterizations and demonstrations will pave the way to
developing new strategies for generating temporally complex drug delivery profiles
(e.g., pulsatile, delayed, and sequential deliveries), thus leading to improved
therapeutic strategies where temporally complex biological processes must be
controlled.
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4.1.

Abstract
Pulsatile chemotherapeutic delivery profiles may provide a number of advantages

by maximizing the anti-cancer toxicity of chemotherapeutics, reducing off-target side
effects, and combating adaptive resistance.

While these temporally dynamic

deliveries have shown some promise, they have yet to be clinically deployed from
implantable hydrogels, whose localized deliveries could further enhance therapeutic
outcomes. Here, several pulsatile chemotherapeutic delivery profiles were tested on
melanoma cell survival in vitro and compared to constant (flatline) delivery profiles of
the same integrated dose. Results indicated that pulsatile delivery profiles were more
efficient at killing melanoma cells than flatline deliveries. Furthermore, results
suggested that parameters like the duration of drug “on” periods (pulse width),
delivery rates during those periods (pulse heights), and the number/frequency of
pulses could be used to optimize delivery profiles. Optimization of pulsatile profiles at
tumor sites in vivo would require hydrogel materials capable of producing a wide
variety of pulsatile profiles (e.g., of different pulse heights, pulse widths, and pulse
numbers). This work goes on to demonstrate that magnetically responsive, biphasic
ferrogels are capable of producing pulsatile mitoxantrone delivery profiles similar to
those tested in vitro. Pulse parameters such as the timing and rate of delivery during
“on” periods could be remotely regulated through the use of simple, hand-held
magnets. The timing of pulses was controlled simply by deciding when and for how
long to magnetically stimulate. The rate of release during pulse “on” periods was a
function of the magnetic stimulation frequency. These findings add to the growing
evidence that pulsatile chemotherapeutic delivery profiles may be therapeutically
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beneficial and suggest that magnetically responsive hydrogels could provide useful
tools for optimizing and clinically deploying pulsatile chemotherapeutic delivery
profiles.
4.2.

Keywords
Chemotherapy, cancer therapy, responsive hydrogels, smart hydrogels, ferrogels,

on-demand drug delivery.
4.3.

Introduction
Cancer is a widespread family of diseases, causing nearly half a million deaths in

the United States in 2016. It is estimated that roughly 40% of American people will be
diagnosed with cancer at some point in their life.1 This motivates the need to develop
new cancer treatment strategies. Traditional cancer treatment strategies involve the
systemic delivery of chemotherapeutics. However, especially for solid tumors which
comprise nearly 85% of cancer cases,2,3 systemic chemotherapeutic deliveries can
have difficulties maintaining drug concentrations at the tumor site and are plagued by
off-target side effects.4,5 Localized deliveries can be achieved from implantable
biomaterials and can circumvent some of the aforementioned problems associated
with systemic chemotherapeutic deliveries.4-15 In fact, several biomaterial-based
chemotherapeutic treatments are on the market (e.g., Gliadel® and Zoladex®).13-15
While localized chemotherapeutic deliveries from hydrogel implants have yielded
promising outcomes, a limitation in their use resides in the fact that the therapeutic
concentrations at tumor sites cannot be altered vs. time after implantation. This
prevents clinicians from altering the course of therapy in responses to updates in
patient prognosis. Additionally, there is a growing evidence suggesting that the
91

sustained delivery profiles produced by traditional chemotherapeutic-eluding
biomaterials (i.e., relatively constant chemotherapeutic concentration vs. time) are not
optimal. For instance, cancer chronotherapies utilize pulsed chemotherapeutic
deliveries in order to expose cancer cells to higher drug concentrations when they are
most susceptible to that drug (e.g., when metabolically active) but when the rest of the
body is less susceptible.17 This approach is based on the fact that tumor cells can
exhibit an accelerated metabolic cycle whereas the rest of the body adheres to a
slower, circadian cycle.18-20

Pulsatile deliveries can also be useful in combating

adaptive resistance—a major hurdle in cancer treatment.21,22 This adaptive resistance
may be particularly problematic when using a hydrogel-based approach since they
provide cancer cells with an exposure profile that is highly amenable to building
resistance (i.e., localized and sustained concentrations). In fact, it has been shown that
that adaptive resistance can be reduced when chemotherapeutic deliveries are paused
and then resumed—a so-called “drug holiday”.21 Taken altogether, these findings
suggest that more pulsatile (i.e., periodically on/off) delivery profiles from implantable
materials could be advantageous in cancer treatment strategies. While hydrogel
materials are highly versatile23 and can provide localized deliveries,4 they do not
inherently provide pulsatile delivery capabilities.
Stimuli-responsive hydrogels6 may provide the on-demand control needed to
produce localized, pulsatile chemotherapeutic delivery profiles. This class of
hydrogels can potentially produce higher delivery rates (establishing higher localized
chemotherapeutic concentrations) when subjected to externally applied stimuli (e.g.,
electrical fields,24 magnetic fields,25-32 and ultrasonic signals)33-35 while only
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producing baseline levels of release when the stimuli is off. Macroporous alginate
ferrogels are of particular interest due to their ability to (i) produce triggered-release
profiles in vivo when exposed to the benign magnetic fields emanating from common
hand-held magnetics,25,26 (ii) impede fibrous capsule formation,36 and (iii) generate
temporally complex delivery profiles, even over the course of days to weeks. 37 While
showing promise in a number of drug delivery applications, these macroporous
ferrogels have not been adapted to deliver the types of pulsatile chemotherapeutic
delivery profiles needed to enhance anticancer activity. For example, a common
chemotherapeutic installment for treating acute myeloid leukemia involves three days
of mitoxantrone delivery,38 and chronotherapies often involve one chemotherapeutic
pulsation

per

day.39

However,

ferrogels

have

been

limited

to

pulsatile

chemotherapeutic deliveries over the course of hours, not days (i.e., 2 min periods of
magnetically enhanced release every half-hour for 3 h total).25 This study therefore
aimed to (i) investigate the impact of different pulsatile chemotherapeutic delivery
profiles on cancer cells in vitro over time scales more pertinent to cancer treatment
(i.e., 1 pulse per day for 3 days) and (ii) demonstrate the ability to magnetically
reproduce multiday, pulsatile delivery profiles using macroporous ferrogels. In pursuit
of these aims, this work also addresses other issues arising from attempting to extend
pulsatile delivery profiles from hours to days. Namely, this work investigates the use
of magnetic field frequency as a means to (i) explicitly regulate the rate of
chemotherapeutic release during pulsation and (ii) maintain control over drug delivery
rates over time as drug becomes depleted from the gel.
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4.4.

Materials and Methods

4.4.1 Materials
B16-F10 mouse melanoma cancer cells were purchased from American Type
Culture Collection (ATCC, Manassas, VA). LIVE/DEAD cell imaging kits were
purchased from Invitrogen (Carlsbad, CA). Sodium alginate (Protanal LF20/40) of
high molecular weight ( 250 kDa) was donated by FMC BioPolymers (Philadelphia,
PA).

Trypan

Blue,

hydroxybenzotriazole

MES

hydrate,

(HOBT),

adipic

acid

dihydrazide

1-ethyl-3-(dimethylaminopropyl)

(AAD),

1-

carbodiimide

(EDC), iron (II, III) oxide powder, sodium chloride, activated charcoal, irinotecan
hydrochloride, 5-fluorouracil, mitoxantrone, Dulbecco’s modified eagle’s medium
(DMEM), fetal bovine serum (FBS), penicillin-streptomycin, and trypsin-EDTA
solutions were all purchased from Sigma-Aldrich (St. Louis, MO). 16-well
xCELLigence e-plates were purchased from ACEA Biosciences, Inc. (San Diego,
CA).
4.4.2 Cell culture and maintenance
B16-F10 mouse melanoma cells were cultured in DMEM with 10% FBS and 1%
penicillin-streptomycin at 37ºC in 5% CO2. B16-F10s were routinely split to avoid
confluence over 70%, roughly every other day, by trypsinizing (5 min with 0.25% w/v
trypsin and 0.5 mM EDTA), collecting, centrifuging, washing, and re-seeding on 75
cm2 flasks.
4.4.3 In vitro melanoma cell survival studies
Cancer cell survival after flatline (constant) mitoxantrone delivery exposures was
compared to those after pulsatile deliveries using B16-F10 mouse melanoma cells in
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vitro.

B16-F10s were seeded at 500 cells per cm2 on 6 well-plates and allowed to

grow in DMEM for 3 days before treatment (Figure 1A, t = -3 d through 0). Then, for
3 days (Figure 1A, t = 0 d through 3 d), B16-F10s were exposed to various
mitoxantrone concentrations vs. time (Figure 1B, schedules s0 – s4). Each of these
delivery schedules (s1 – s4) utilized the same integrated amount of mitoxantrone (666
ng mL-1 day-1). Varying mitoxantrone concentration vs. time was achieved by
exchanging fresh DMEM with measured concentrations of mitoxantrone in DMEM.
When transitioning from mitoxantrone-containing media to mitoxantrone-free media,
cells were rinsed 3 times in fresh media in order to remove any residual mitoxantrone.
After 3 days of treatment, cells were washed 3 times with DMEM so that no residual
mitoxantrone was left and allowed to grow for a day in fresh DMEM (Figure 1A,
“recovery” t = 3 d through 4 d).
Cell viability was quantified on day 3 and day 4 using a LIVE/DEAD staining
assay. Also, culture population was monitored in real-time using 16-well
xCELLigence e-plates. E-plates wells (similar in size as 96-well plates) were plated on
day -3 at 500 cells per cm2 and allowed to grow for 3 days (days -3 through 0) before
mitoxantrone treatment for 3 more days (days 0 through 3) following the same
timeline as provided in Figure 1A. Mitoxantrone concentrations were altered as
described above. xCELLigence software was used to collect real-time cell index data
for later analysis and plotting. Because cell index values—which represents cell
population vs. time based on measured impedance—can be variable from experiment
to experiment, cell index values were normalized so that values were set to 1 across all
conditions at time 0, when mitoxantrone treatment began.
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Figure 1. (A) A timeline describing the in vitro cytotoxicity experiment where B16F10 cells were seeded and allowed to grow for 3 days before treatment, exposed to
mitoxantrone treatment profiles s0 – s4 for 3 days, and allowed to recover for a day.
(B) Delivery schedules (s0 – s4) were used on B16-F10 cells where the integrated
dose was maintained at 666 ng mL-1 day-1.
4.4.4 Biphasic ferrogel fabrication
To make magnetically responsive hydrogels, alginate was purified through
dialysis (3500 MW cutoff, Spectrum Labs, Compton, CA), activated charcoal
treatment, filtration, and lyophilization. In a manner previously described,26,37 alginate
was dissolved in MES buffer (pH = 6.5) with AAD, and iron oxide powder to form a
solution containing 7 wt % iron oxide, 1 wt % alginate, 2.5 mM AAD crosslinker.
Crosslinking was initiated using EDC and the hydrogels were cast between two glass
plates spaced 2-mm apart with a magnet placed on top as to pull the iron oxide to one
side of the gel, achieving a biphasic structure (Figure 2A). Here, biphasic ferrogel
structures were used due to their demonstrated ability to provide higher levels of drug
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delivery under similar magnetic stimulation conditions when compared to monophasic
designs.26

(A)
Casting gel w ith magnet

(B)

(C)

Sw elling in DI w ater Freezing at -20oC

N
S

(D)

(E)

Lyophilizing

Biphasic ferrogel

H2O

5 mm

Fe3O4

Figure 2. A schematic of the biphasic ferrogel fabrication process. (A) Gels were cast
between two glass plates with a magnet on top, (B) allowed to swell in DI water after
gel formation, (C) frozen at -20oC to form ice crystals, and (D) lyophilized to
evaporate ice crystals, leaving pores. (E) Photograph of a completed macroporous
biphasic ferrogel.
After gelation (40 minutes), individual 8-mm diameter cylindrical gels were cut
using a biopsy punch and were rinsed in deionized water for 3 days (exchanging liquid
3-times daily) (Figure 2B). This removed residual reagents from the gel and allowed
the gel to swell fully. Gels were then frozen at -20ºC (Figure 2C) and lyophilized
(Figure 2D). The resulting structure was an 8 x 2 mm cylindrical dehydrated,
macroporous, biphasic ferrogel (Figure 2E).
4.4.5 Electron microscopy imaging of ferrogels
Structural analyses of freeze-dried ferrogels were performed using Scanning
Electron Microscopy (SEM) with a Zeiss SIGMA VP Field Emission-Scanning
Electron Microscope (FE-SEM). Backscattered electron imaging was done using
identical conditions at an accelerator voltage of 20 keV and a chamber pressure of
97

5×10-6 torr. No sputter coating was applied to the ferrogels for imaging.
4.4.6 Biphasic ferrogel release studies
Lyophilized ferrogels were loaded with known amounts of mitoxantrone by
adding precise volumes of drug solutions to the lyophilized gels. It was determined
that ferrogels would absorb no more than 65 μL of liquid. Thus, solutions containing
125 μg of mitoxantrone per 65 μL of PBS were prepared and added dropwise to the
iron-oxide-free side of ferrogels (i.e., the white side of the biphasic gel, Figure 2E)
and allowed to soak in overnight while sealed in a scintillation vial. This amount of
mitoxantrone loading (125 μg per gel) represents an experimentally optimized loading
that does not saturate the ferrogel with mitoxantrone (see Supporting Information,
Section 1, Figure S1). This lack of saturation reduces the amount of diffusive
mitoxantrone release when not magnetically stimulated and enables therapeutically
relevant release rates when stimulated (single-digit micrograms per hour). To remove
unincorporated mitoxantrone, ferrogels were then soaked in 5 mL of PBS for 1 hour. It
was found that this method of loading resulted in over 80% of the original 125 μg of
mitoxantrone to be taken up by the ferrogels and that subsequent rinsing removed very
little beyond that (Figure S2). That is, after loading, an average of 103.3 μg of
mitoxantrone was taken up by the ferrogels, and rinsing reduced this amount to an
average of 101.4 μg. This amount of mitoxantrone represents the drug contained in the
gels prior to release studies and is used to compute the amount of drug remaining (%)
vs time. Immediately following rinse, gels were placed in 1 mL of PBS and the release
study was initiated. Ferrogel-containing scintillation vials were placed on top of a
custom magnet stimulation system (see next subsection) and exposed to various
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magnetic stimulation signals (or no signal for control experiments). Samples were
taken periodically by fully removing the 1 mL of PBS, reserving it for later analysis,
and replacing it with a fresh 1 mL of PBS. The concentration of mitoxantrone
contained in collected samples was quantified using BioTek Cytation3 microplate
reader to measure optical absorbance at 610 nm for mitoxantrone against a standard
curve.
4.4.7 Custom magnetic stimulation system
To expose ferrogels to a wide variety of magnetic stimulation frequencies, a
custom magnetic stimulation system was designed and built (Figure 3). This system
consisted of an electric motor whose speed could be controlled through a computer
interface. This electric motor drove a crankshaft which drove four balanced, in-line
pistons. Each piston held a single 1.27 x 1.27 cm cylindrical neodymium magnet (K&J
Magnetics, Inc., Pipersville, PA) whose vertical position cyclically raised and lowered
as the electric motor ran. A scintillation vial was held on a platform just above each
piston in a manner that held ferrogel samples close to the magnets at maximum height
but far enough away to avoid physical contact with the magnet. Thus, four ferrogels
could be simultaneously exposed to cyclic magnetic gradients at frequencies
prescribed by the motor speed (between 0.01 and 20 Hz). Ferrogel samples contained
within their scintillation vials were exposed to between 0 and 5.6 kGauss at piston
minimum and maximum positions, respectively, as measured by Hall-effect sensors.
Three movies are provided in Supporting Information that shows this device in use at
0.1 Hz, 1 Hz, and 10 Hz (MovieS1.mov, MovieS2.mov, MovieS3.mov, respectively).
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Figure 3. Schematic (top) and photograph (bottom) of the custom magnetic
stimulation setup used in these studies.
4.4.8 Data representation and statistical analyses
All quantitative data presented here are represented by means ± standard
deviation, unless otherwise specified. For all statistical analyses, Analysis of Variance
(ANOVA) was used with Tukey’s post-hoc tests for multiple comparisons (using
Kaleidagraph software) and p-values of less than 0.05 being our benchmark for
statistical significance. *, ** and *** indicates statistical significance of p < 0.05,
0.01, and 0.001, respectively. n.s. indicates no statistical significance. (p > 0.05).
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4.5.

Results

4.5.1 Continuous vs. pulsatile chemotherapeutic deliveries on tumor cells in vitro
To determine if pulsatile chemotherapeutic deliveries were more toxic to cancer
cells than continuous (flatline) deliveries, B16-F10 mouse melanoma cells were
exposed to various mitoxantrone concentration profiles vs. time over the course of 3
days (see Figure 1). Despite using the same integrated doses of mitoxantrone (666 ng
mL-1 day-1), it was determined that pulsatile delivery schedules could result in lower
numbers of live melanoma cells than continuous profiles (Figure 4A). Specifically,
immediately after mitoxantrone treatment (Figure 1A, day 3), all three pulsatile
delivery schedules tested (schedules s2 – s4) resulted in significantly fewer live
melanoma cells than the continuous schedule s1 (Figure 4B, left). However, when
given a full day to recover after mitoxantrone treatment (Figure 1A, day 4), cells
exposed to schedule s4 recovered somewhat (Figure 4B, comparing blue and red bars
for s4). Notably though, pulsatile schedules s2 and s3 remained at low levels (Figure
4B, red and blue bars for s2 and s3 remained low).
Pulsatile delivery profiles may have resulted in lower melanoma cell survival than
the constant profile due to (i) improved prevention of the cells developing resistance to
the drug, but also simply due to (ii) the use of temporary and periodically higher
dosing. That is, while the same amount of total drug was used in schedules s1−s4,
pulsatile delivery schedules required that higher concentrations be delivered during
“on” phases of the delivery profile to match the total integrated dose of the continuous
profile. Thus, during these “on” phases, cells were exposed to more toxic
concentrations

of

mitoxantrone.

Notably,
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however,

when

very

toxic/high

concentrations were used but for very short “on” periods (i.e., schedule s4: 192 μg/mL
but only held for 15 min per “on” period), melanoma cell elimination became less
effective (Figure 1B, s4).
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Figure 4. Pulsatile temporal delivery profiles enhance the toxicity of mitoxantrone
exposure when compared to constant delivery profiles. (A) Fluorescence microscopy
images of B16-F10 cells after LIVE/DEAD (green/red) staining on day 4 after 3 days
of exposure to schedules s0 – s4 and a day of recovery. (B) Quantification of live
cells after the indicated delivery schedules immediately after treatment (left, blue) and
after a day of recovery (right, red). N = 6. (C) Left: Normalized cell index (melanoma
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cell population) vs. time when exposed to no mitoxantrone (dashed black), constant
mitoxantrone concentration (s1, solid black), and a pulsed mitoxantrone profile (s3,
solid green). Right: Zoomed-in index vs. time for cells exposed to pulsatile schedule
s3. Blue rectangles indicate where the mitoxantrone pulses are “on” for the s3
condition. N = 4.
This could be attributed to there not being a sufficient amount of time for the
drug’s toxicity to manifest. In the case of this chemotherapeutic, mitoxantrone
molecules must be able to internalize and access the cell nucleus where it can disrupt
DNA synthesis and repair mechanisms. In fact, mitoxantrone is known to rapidly
absorb to tissues38 with absorption half-lives reported to be on the order of 10 min.40
Thus, for fleeting drug exposures on the order of that time scale (e.g., 15 min), only a
fraction of mitoxantrone would be expected to absorb and have a therapeutic impact
on the cells. Of the four mitoxantrone schedules tested, the pulsatile schedule s3 (24
μg/mL held for 2 h per “on” period) yielded the most significant reduction in
melanoma cell survival (Figure 4B, right). This may represent a more effective
balance of increased mitoxantrone concentrations being held for a sufficiently long
period of time (i.e., about 12 half-lives) to reach and interact with intercellular targets.
To test how the number/frequency of pulses impacted melanoma cell survival,
experiments were conducted where B16-F10s were seeded, allowed to grow, exposed
to different mitoxantrone pulsed profiles at the same integrated dose, and left to
recover after treatment, all while being monitored for cell index in real time (Figure
5A). Here, pulsatile delivery profiles were either a single pulse (Figure 5B, p1), two
pulses (p2), or three pulses (p3), and compared to a constant (flatline) delivery profile
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(p0). Results indicate significant differences between the number of live melanoma
cells remaining after pulsed mitoxantrone treatments with different numbers of 2-h
pulses (Figure 5C). In particular, the two-pulse delivery profile (Figure 5C, schedule
p2, blue curve) appeared to be the most effective in eliminating melanoma cells.
Whiles these effects are the subject of ongoing investigations, schedule p2 may
present an effective combination of sufficiently high pulsed dosing repeated enough to
be most toxic to melanomas.

Figure 5. For pulsatile mitoxantrone deliveries, the number of pulses can have an
impact on how many melanoma cells survive treatment. (A) A timeline describing the
in vitro experiments was conducted. (B) Schematics describing the different pulses

104

mitoxantrone delivery schedules used (0−3 pulses, schedules p0−p3, respectively). (C)
Normalized cells index for melanoma cells vs time during mitoxantrone treatment
(blue shaded region) and after treatment for cells exposed to schedules p0 (black), p1
(red), p2 (blue), and p3 (green). ** indicates statistically significant differences with p
< 0.01 as computed using one-way ANOVA with Tukey’s post hoc tests for multiple
comparisons. N = 4.
Taken together, these data indicate that pulsatile delivery profiles may provide
advantages over constant (flatline) delivery profiles. Systemic delivery of pulsatile
profiles may be problematic, however, since periodically high concentrations of
chemotherapeutics may impose undesirable side effects. These issues could be
reduced if deliveries were more localized, for instance, by using a drug-releasing
hydrogel implanted at the tumor site. However, traditional hydrogels do not provide
pulsatile delivery profiles. This work will therefore investigate if pulsatile deliveries
can be administered over the course of several days (mimicking the deliveries here)
using magnetically responsive biphasic ferrogels.
4.5.2 Biphasic ferrogels for magnetically controlled drug delivery profiles
In order to produce hydrogels capable of generating pulsatile deliveries similar to
those investigated in the previous section, biphasic ferrogels26,36,37 were fabricated.
These cylindrical gels consisted of (i) an iron-oxide-laden region and (ii) a soft and
deformable porous alginate region (Figure 6A). The particular ferrogel formulation
used here (7 wt % iron oxide, 1 wt% alginate, 2.5 mM AAD crosslinker, freeze-dried
at -20ºC) was previously optimized to provide maximal deformation and drug delivery
when exposed to hand-held magnets.26 After lyophilization, these ferrogels’ alginate
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regions could absorb concentrated solutions of mitoxantrone (Figure 6B, i & ii,
mitoxantrone is dark blue). Ferrogels were capable of releasing loaded mitoxantrone
earnestly when magnetically compressed with a hand-held magnet and returned to
their original shape between compressions (Figure 6B, iii).

Figure 6. Magnetically responsive biphasic ferrogels were porous in structure and
capable of magnetically triggered drug delivery. (A) (i) Photograph of a whole
biphasic ferrogel (left) and its cross-section (right). SEM images of the iron-oxideladen region (ii), porous alginate region (iii), and the transition between the two
regions (iv). Elemental mapping data show iron (yellow) and carbon (blue). (B)
Photographs of a flipped and lyophilized ferrogel prior to drug loading (i), a ferrogel
during loading (ii), and a loaded ferrogel being repeatedly stimulated with a hand-held
magnet (iii).
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4.5.3 Generation of pulsatile mitoxantrone profiles from biphasic ferrogels
Biphasic ferrogels were loaded with mitoxantrone and stimulated with magnetic
signals, periodically, in order to generate pulsatile delivery profiles. Specifically, the
strategy adopted here was to (i) magnetically stimulate at 1 Hz (i.e., 1 magnetic
compression per second) during “on” periods in order to generative temporarily higher
mitoxantrone release rates and (ii) not magnetically stimulate during “off” periods in
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order to generate lower mitoxantrone release rates (Figure 7A).
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Figure 7. Biphasic ferrogels generate pulsatile delivery profiles when periodically
stimulated with hand-held magnets. (A) Schematic of the 1 Hz magnetic frequency
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stimulation profile used. (B) Mitoxantrone release rate vs. time for magnetically
stimulated ferrogels (blue) compared to unstimulated controls (black). (C) Percent of
mitoxantrone remaining in ferrogels vs. time for stimulated (blue) and unstimulated
(black) ferrogels. N = 4.
This magnetic stimulation profile did result in periodically higher mitoxantrone
release rates as compared to control ferrogels that were not magnetically stimulated
(Figure 7B, comparing the height of blue and black curves during “on” periods).
Note that even control ferrogels exhibited slightly increased release rates during “on”
periods, even though no magnetic stimulation was applied during these times.
This was attributed to the agitation associated with removing and adding fresh
media during sample collection and reestablished concentration gradients across the
perimeter of the gels when fresh media was added. Nevertheless, magnetic stimulation
still resulted in statistically significant increases in mitoxantrone release rate during
each “on” periods compared to controls (Figure 7B, p < 0.01 at 0, 24, and 48 hours).
While these data show promise, one observed issue was that the magnetically
triggered “on” release rates were not consistently high on subsequent days. That is, the
release rate achieved through magnetic stimulation deceased each day, despite being
stimulated with the same stimulations on each day (Figure 7B, blue curve, descending
pulse height at 0, 24, and 48 hours). This was attributed to the depletion of
mitoxantrone remaining in the gel over time (Figure 7C). As time progressed, less
mitoxantrone was available to be magnetically squeezed out of the gel, therefore
generating lower release rates when magnetically stimulated. This depletion issue will
be addressed in the following subsection. The other observed issue was that the release
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rates during “on” periods were not explicitly controlled. That is, magnetic stimulation
generally enhanced release rates, but the degree of this enhancement was not dictated
by the magnetic stimuli. This will be addressed in the next subsection.
4.5.4 Regulating chemotherapeutic release rate using the frequency of magnetic
stimulation
The ability to remotely regulate the release rate of chemotherapeutics during “on”
periods would be very desirable as it would enhance the ability to control the release
characteristics after implantation. It was hypothesized that stimulating at higher
frequencies would increase the rate of release. That is, when compressed more times
within a given window of time, more drug would be convectively purged from the
ferrogel. Therefore, the frequency of magnetic stimulation could potentially be used as
a way to remotely regulate the rate of release. In order to test this hypothesis, biphasic
ferrogels were loaded with mitoxantrone and stimulated for 10 minutes at different
magnetic frequencies. It was determined that increasing frequencies from 0.1 to 10 Hz
did increase the amount of mitoxantrone released (Figure 8).
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Figure 8. The rate of release can be regulated by stimulating at different frequencies.
Percent of drug released after 10 minutes of magnetic stimulation at the indicated
magnetic stimulations: no magnetic stiulatinon control (black), 0.1 Hz (yellow), 1 Hz
(blue) and 10 Hz (green). N = 4.
Based on these results, it was also hypothesized that the frequency of magnetic
stimulation could be used to generate different release rates during “on” phases of a
pulsatile delivery schedule. In other words, it was thought that frequency could be
used to remotely regulate pulse “height.” In order to test this, experiments similar to
those presented in Figure 7 were conducted but using frequencies of 0.1, 1, and 10 Hz
used during “on” periods (Figure 9A). During the first “on” period, different magnetic
stimulation frequencies resulted in statistically different release rates (Figure 9B, day
1 results). However, during subsequent “on” periods, the use of different frequencies
to generate different release rates became progressively less effective (Figure 9B, day
2 and day 3 results). In fact, by the time the day 3 “on” period was magnetically
triggered, there was no statistical difference between any condition (Figure 9B, day 3
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results). This effect was attributed to, again, depletion of available mitoxantrone in the
gels. As time progressed, less mitoxantrone was available for release (Figure 9C),
making it more difficult to magnetically purge drug for all stimulation frequencies.
During the first “on” period, different magnetic stimulation frequencies resulted
in statistically different release rates (Figure 9B, day 1 results). However, during
subsequent “on” periods, the use of different frequencies to generate different release
rates became progressively less effective (Figure 9B, day 2 and day 3 results). In fact,
by the time the day 3 “on” period was magnetically triggered, there was no statistical
difference between any condition (Figure 9B, day 3 results).

This effect was

attributed to, again, depletion of available mitoxantrone in the gels. As time
progressed, less mitoxantrone was available for release (Figure 9C), making it more
difficult to magnetically purge drug for all stimulation frequencies.
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Figure 9. Stimulation at different frequencies yielded different release rates during
“on” periods initially, but significant differences were not achieved at later time
points. (A) Mean mitoxantrone release rate vs. time for ferrogels exposed to no
stimulation (black), 0.1 Hz (red), 1 Hz (blue), and 10 Hz (green) at the indicated times
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(red, blue, and green shaded regions, respectively). (B) Mean and standard deviation
of release rates during “on” periods for days 1 (left), 2 (middle), and 3 (right) for the
same conditions shown in (B) Mean and standard deviation of release rates during
“on” periods for days 1 (left), 2 (middle), and 3 (right) for the same conditions shown
in part (A). (C) Percent of mitoxantrone remaining in gels vs. time for the same
conditions shown in part (A). N = 4.
4.5.5 Pulsatile delivery schedules with consistent “on” period release rates vs. time
Because mitoxantrone could be more efficiently released when using higher
stimulation frequencies, it was thought that higher stimulation frequencies could be
used to compensate for reduced release rates as time progressed due to drug depletion.
Specifically, the strategy was to use progressively higher stimulation frequencies in
order to maintain more consistent release rates as the drug became more difficult to
magnetically purge from the gel (due to there being a less available drug). Therefore,
experiments were conducted where subsequent “on” periods used stimulation
frequencies of 0.08 Hz, 0.8 Hz, and 8 Hz (Figure 10A). This progressive magnetic
stimulation profile resulted in pulsatile mitoxantrone delivery profiles with consistent
pulse heights (Figure 10B). These “on” period release rates were statistically similar
on days 1 – 3 and each higher than controls (Figure 10C). Likewise, the amount of
drug remaining in the gels more consistently dropped during subsequent stimulations
(Figure 10D, drops during times shaded in gray).
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Figure 10. “On” period release rates could be more consistent vs. time when
progressively higher stimulation frequencies were used. (A) Schematic of the
magnetic stimulation profile used. (B) Release rate vs. time when subjected to the
magnetic stimulation profile described in part (A). (C) Releaser rates during “on”
periods on days 1, 2, and 3 for unstimulated control gels (black) and gels exposed to
the progressive stimulation profile (green). (D) Percent of mitoxantrone remaining in
the gels vs. time. N = 4.
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4.5.6 Extending the duration of Pulsatile deliveries from Ferrogels beyond Three
Days.
While the 3-day pulsatile profiles used in these in vitro studies (Figure 1B) and
those generated magnetically from ferrogels (Figure 10B) were based on (i) existing
mitoxantrone chemotherapies (e.g., a recommended treatment for acute myeloid
leukemia involves 3-day mitoxantrone delivery installments)38 and (ii) the fact that
chronotherapies often involve one chemotherapeutic pulse per day,39 other emerging
therapies could require pulsed delivery profiles extending beyond 3 days. Thus, to
investigate ferrogels’ abilities to produce pulsatile mitoxantrone delivery profiles for
durations longer than 3 days, a magnetic stimulation profile was tested that used
progressively higher magnetic stimulation frequencies on subsequent days over the
course of 8 days (Figure 11A). Note, however, that the magnetic stimulation setup
(Figure 3) permitted only stimulations up to 10 Hz (requiring the electric motor to run
at 600 rpm). Thus, on days 4 through 8, magnetic stimulation frequency was maxed
out at 10 Hz. Nonetheless, magnetically triggered pulse heights were statistically
higher than control gels through day 7 and statistically indifferent from each other
through day 5 (Figure 11B). Note that elsewhere, increased mitoxantrone release rates
have been delivered from biphasic ferrogels at frequencies up to 40 Hz using
electromagnets (without moving parts) to generate these higher frequencies.37 Thus, it
may be possible to compensate for drug depletion for longer durations than achieved
here by continuing to progressively increase stimulation frequency beyond 10 Hz.
Also note that though the day-8 magnetically triggered pulse did not meet our
benchmark for being statistically higher than controls, it did exhibit a modestly low p-
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value (p = 0.057). On day 8, some of the ferrogels began losing their structural
integrity after being so aggressively stimulated on subsequent days (5 days straight at
10 Hz).

Figure 11. Pulsatile mitoxantrone delivery schedules from ferrogels can be extended
beyond 3 days. (A) Table detailing the magnetic stimulation profile used. On each
day, 1 h of magnetic stimulation was performed at the indicated frequency. (B)
Mitoxantrone release rate vs time when subjected to the magnetic stimulation profile
described in part A (blue) compared to controls (black). (C) Percent of mitoxantrone
remaining in the gels vs time for magnetically stimulated gels (blue) compared to
controls (black). Asterisks indicate levels of statistical differences for given pulse rates
compared to controls (see Section 2.8). † indicates that magnetically triggered release
rate is statistically lower than triggered rates achieved on other days (0.03 < p < 0.05).
N = 4.
This loss of structure likely enabled more drug release from some of the gels, thus
leading to higher standard deviations in the release data and thus a lack of statistically
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significant differences when compared to controls. Future ferrogel designs will have to
be more robust to facilitate the delivery of prolonged pulsed profiles (i.e., those lasting
weeks), though gels held up amply during 3-day pulsatile deliveries, which were
shown to be very effective against melanoma cells in vitro (Figure 4).
4.6.

Discussion
These studies demonstrate that pulsatile delivery schedules could provide

enhancements in the anti-cancer activity of chemotherapeutics and that magnetically
responsive hydrogels could be used to locally deliver these types of pulsatile
schedules. The findings here that pulsatile delivery profiles are more effective in
eliminating cancer cells than constant profiles of the same integrated dose are
consistent with (i) other studies that have found that short bursts of high mitoxantrone
concentrations are more effective in destroying breast cancer cells,33 (ii) findings that
cancer cells respond to drug exposures more dynamically than once thought,18,41 and
(iii) indications that dynamical drug exposures can have significant impact on cellular
responses.42 If delivered in vivo, pulsatile drug scheduling may also enjoy some of the
added benefits associated with chronotherapies. For example, pulsing drug
concentrations may be a more effective means to deliver toxins when tumor cells are
most susceptible to the drug and while off-target tissues are less susceptible.17-20 Also,
turning drug concentrations on and off may be useful in combatting adaptive
resistance.21

While the work presented here adds to the growing evidence that

pulsatile delivery schedules are beneficial, it is important to note that the specific
delivery profiles examined here do not represent full optimizations. Namely, more
complete optimizations will require testing a wider range of pulsatile profiles with
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different “on” period delivery rates (pulse heights), “on” period durations (pulse
widths), and frequencies of pulsing. Optimizations will also need to be tested in vivo,
through systemic delivery of these pulsatile profiles would likely pose problems since
periodic overdosing could exacerbate off-target side effects. This motivates the need
for implantable drug-delivery materials capable of delivering pulsatile profiles locally
at tumor sites. This, in turn, requires hydrogels that can generate a wide variety of
different pulsatile delivery schedules (i.e., various pulse widths/heights and
frequencies) so that delivery schedules can be experimentally optimized.
The magnetically responsive hydrogels developed here were capable of producing
pulsatile mitoxantrone delivery profiles similar to those tested on melanoma cells in
vitro (i.e., pulsed over the course of 3 days). Critically, pulsatile delivery parameters
such as the timing and delivery rates of pulses could be remotely controlled using
magnetic fields emanating from simple hand-held magnets. Specifically, the timing
and duration of “on” periods were controlled simply by choosing when and for how
long to magnetically stimulate. Rates of delivery during “on” periods were also
capable of being remotely regulated by applying different magnetic stimulation
frequencies. Applying different stimulation frequencies allowed for different “on”
rates initially or could be used to maintain more consistent release rates as the gels
became depleted of the drug over time. While the use of these magnetically responsive
ferrogels could provide the above-outlined clinical advantages, devices must first be
commercially developed to magnetically stimulate implanted ferrogels over a range of
frequencies. This could be achieved using simple electromagnets, which have been
demonstrated to efficiently regulate mitoxantrone release rates from biphasic ferrogels
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at stimulation frequencies up to 500 Hz.37
Elsewhere, magnetically compressible ferrogels were shown to be capable of
delivering molecular payloads after implantation in vivo.25 In fact, their cyclic
magnetic compressions have actually been shown to resist fibrous capsule formation.36
Previous studies have demonstrated the ability to magnetically generate pulsatile
mitoxantrone deliveries from ferrogels. Zhao et al. 25 demonstrated that magnetic fields
could be used to periodically enhance release rate from magnetically compressible
ferrogels when stimulated for 2 min every half hour for 3 h. This resulted in
significantly enhanced amounts of release after 3 h compared to controls. The work
presented here builds upon the work of Zhao et al. by extending the timeframes of
pulsatile release to durations thought to be relevant to chemotherapies and
chronotherapies (e.g., days)19−22 and demonstrating that specific pulsatile deliveries
profiles produced by ferrogels have beneficial impact on destroying tumor cell
populations. Additionally, by extending these timeframes, magnetic stimulation
strategies had to be developed to maintain delivery rates to compensate for drug
depletion over time. Finally, this work builds upon previous work by devising
strategies for controlling the degree of enhanced delivery rate during magnetic
stimulation using the frequency of magnetic stimulation to remotely regulate release
rates. Taken altogether, the studies presented here (combined with their in vivo
capabilities demonstrated elsewhere) suggest that these magnetically responsive
hydrogels could be used to deliver more temporally complex and effective
chemotherapeutic delivery profiles to tumor sites in future studies with the degrees of
on-demand control needed to (i) experimentally optimize delivery profiles and (ii)
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clinically alter the course of therapies according to up-to-date prognoses.
4.7.

Conclusions
These studies demonstrate that pulsatile delivery profiles of a chemotherapeutic

(mitoxantrone) are more effective at eliminating melanoma cells than constant
(flatline) deliveries of the same integrated dose in vitro. Some pulsatile profiles
worked better than others (i.e., schedule s3 was most effective: 24 μg/mL for 2 h
during “on” periods, 22 h “off” periods, repeated for 3 days). However, a more
complete optimization of delivery profiles will require testing a broader range of
delivery profiles in vivo. This work has also demonstrated that a magnetically
responsive, biphasic ferrogel can be used to generate pulsatile mitoxantrone delivery
profiles similar to those tested on melanoma cells in vitro. The timing of mitoxantrone
pulses could be regulated by choosing when to apply magnetic stimuli (i.e., from
simple hand-held magnets). The rate of delivery during magnetic stimulation could be
regulated by stimulating at different magnetic field frequencies. Thus, these materials
could potentially streamline the optimization of pulsatile deliveries by enabling the
production of a wide variety of pulsatile profiles directly to tumor sites through ondemand, magnetically triggered stimulations. Finally, these materials could also
provide powerful tools for clinically deploying optimized pulsatile delivery profiles at
tumor sites, while retaining the real-time control needed to alter the course of therapies
on-the-fly.
4.8.

Associated Content
The Supporting Information is available free of charge on the ACS Publications

website at DOI: Movies of custom magnetic stimulation setup.
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5.1.

Abstract
Sequential protein release is required in regulating many biological processes that

underlie injury and disease. A magnetically responsive dual-compartment biomaterial
was therefore designed and successfully applied to provide on-demand sequential
release of proteins relevant to specific therapies that would benefit from sequential
release. The composition of this biomaterial system consists of a gelatin outer
compartment and a ferrogel inner compartment. Three pairs of relevant proteins were
incorporated in the biomaterial system: (1) Granulocyte-Macrophage ColonyStimulating Factor (GM-CSF, a dendritic cell recruitment factor) and Heat Shock
Protein 27 (HSP27, as a model cancer antigen) for use in cancer immunotherapy; (2)
Vascular Endothelial Growth Factor (VEGF, an angiogenic sprouting factor) and
Platelet Derived Growth Factor (PDGF, a factor that aids in maturing vascular sprouts)
for tissue vascularization; and, (3) Stromal cell Derived Factor-1α (SDF-1α, a bone
progenitor cell recruitment factor) and bone morphogenetic protein 2 (BMP2, a osteodifferentiation factor) for bone regeneration. It was demonstrated that proteins loaded
in the outer compartment (GM-CSF, VEGF, SDF-1α) released rapidly within the first
24 to 100 hours and that the amount released was dependent on how much protein was
loaded in the compartment. timing and rate of release of these proteins can be
controlled via magnetic stimulation. Proteins loaded in the inner ferrogel (HSP27,
PDGF, BMP2) could be magnetically triggered to provide delayed enhancements in
release rate where the timing (between days 1 and 8) and rate of release (0.2 to 1
ng/hr) were externally controlled through the temporal profile of magnet application
and the frequency of that application.

This biomaterial system can be used to
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investigate how the timing and sequence of protein deliveries impacts the biological
processes that underlie cancer immunotherapy, tissue vascularization, and bone
regeneration (and potentially in many other therapeutic areas) and can be used to
experimentally optimize deliveries in these therapies.
5.2.

Introduction
Hydrogels have been commonly used as biomaterials in drug delivery and tissue

engineering applications due to their biocompatibility and versatility. [1]–[3] These
drug delivery materials can potentially control important biological processes that
need to be regulated to treat injury and disease. However, most biologics are
sequential in nature and require sequential presentations of bio-instructive factors for
proper regulation. For example, cancer is the second most common cause of death in
the United States and accounts for nearly 1 of every 4 deaths. [4] This emphasizes the
necessity of finding effective cancer treatment strategies. One promising cancer
treatment strategy is biomaterials-based immunotherapy in which the immune system
of the patient’s own body is reprogramed in order to initiate an immunological attack
against cancer cells. [5]–[7] In this approach, first, dendritic cells (DCs) need to be
recruited to the biomaterial by releasing a DC recruitment factor (Factor I) (Fig 1.A.i,
ii). Once a large number of DCs are resident in the biomaterial (Fig 1.A.iii), they can
become activated when presented with a cancer antigen (Factor II) (Fig 1.A.iv).
Activated DCs would then migrate out of the biomaterial towards lymph node (Fig
1.A.v), triggering an immunological attack against cancer. Therefore, sequential
release of recruitment factor followed by release of activating factor could potentially
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improve control over regulating the biological processes pertinent to biomaterial-based
cancer immunotherapies.
Beyond cancer treatments, regulation of vascular growth can be of great potential
in the treatment of different cardiovascular diseases (CVDs), which are the most
common cause of death in the United States and worldwide. [8] It has been reported
that CVD was the main cause of more than 50% of deaths in 2010. [9] Additionally,
regeneration of tissues after surgery or injury often involves regulating the growth of
new vascular networks. [10]–[12] Pericyte cells play a key role in vessel formation
and presentation of several growth factors can regulate this process.[13] For example,
growth of new blood vessels can be initiated by an initial presentation of angiogenic
factors (Factor I) which instructs pericyte cells to detach from the endothelium of
nearby vasculature. This detachment destabilizes the endothelium and allows small
vascular sprouts to grow away from the existing blood vessel (Fig 1.B.i, ii). These
nascent sprouts are thin, unorganized, and not mature enough to efficiently perfuse
blood through them (Fig 1.B.iii). Hence, an additional maturation factor (Factor II) is
subsequently released to recruit pericyte cells back to neovessels (Fig 1.B.iv), which
in turn helps neovessels mature into a thicker and more interconnected network (Fig
1.B.v).
Finally, sequential delivery of bio-instructive factors can be of potential value in
regenerating bone tissues. Each year more than 6 million bone fractures occur in the
United States, leading to approximately 900,000 patient hospitalizations.[14]
Biomaterial scaffolds can be promising substitutes for traditional autogenic and
allogenic grafting since they can decrease the problems associated with donor site
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sensitivity, morbidity, and limited availability of these grafts.[15], [16] Bone
regeneration also is naturally regulated by a sequence of growth factor
presentations.[17] First, osteoprogenitor cells need to be recruited to the scaffold by
releasing a bone progenitor recruitment factor (Factor I) (Fig 1.C.i, ii). After
establishing a population of these progenitor cells in the biomaterial (Fig 1.C.iii), they
can be differentiated down the osteogenic lineage by exposing them to a osteodifferentiation factor (Factor II) (Fig 1.C.iv). Differentiated bone cells would then
start secreting their own robust bone matrix, which is a vital step in regenerating new
bone tissues (Fig 1.C.v).Therefore, in order to better regulate these regenerative
processes, sequential delivery of bone progenitor recruitment and differentiation
factors is necessary.

Figure 1. Sequential delivery of multiple factors is essential for improved outcome in
multiple therapies. A) Schematic showing how sequenced deliveries could be
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beneficial for biomaterial-based cancer immunotherapy B) tissue vascularization and
C) bone regeneration.
In previous studies, hydrogels were demonstrated to have sequentially protein
release capabilities using formulations containing phases with different degradation
rates. However, the timing between these two deliveries was not capable of being
regulated after implantation or injection of these biomaterials. [18]–[20] Additionally,
these delivery profiles can more aptly be described as dual deliveries with different
rates and not sequential release per se (i.e., on burst release followed by a second,
delayed burst release).

Figure 2. New Biomaterial system is designed to improve sequential delivery of
several factors in an on-demand manner. A) Schematic of the multi-compartment
biomaterial system shows how delivery of multiple factors can be accomplished in a
controlled sequenced manner B) Desired cumulative release of factor I and II. C)
Table shows different therapies and factors mediating these processes.
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The biomaterial system presented here was specifically designed to provide
sequential delivery profiles where there is an initial burst release of one factor
followed by a magnetically triggered, delayed release of a second factor. This was
achieved by composing the biomaterial with two compartments (Fig 2.A.i, ii).
Compartment 1, initially releases Factor I and has a functionality to maintain recruited
cells (Fig 2.A.iii, iv). Compartment 2 is capable of releasing Factor II in an ondemand manner when remotely stimulated with a magnetic field (Fig 2.A.v). This
study aimed to demonstrate the ability to generate these sequential delivery profiles
for specific recruitment factors (GM-CSF, VEGF, SDF-1α) followed by magnetically
triggered delivery of programming factors (HSP27, PDGF, BMP2) (Fig 2.B), which
are relevant to regulating sequential biologies in cancer immunotherapy, generation of
new vascular networks, and in regenerating bone tissues, respectively (Fig 2.C).
5.3.

Experimental

5.3.1 Materials
High guluronate content sodium alginate (Protonal LF 20/40) with molecular
weight of ~ 250 kDa was provided by Pronova Biopolymers (Olso, Norway). Other
chemicals such as Adipic Acid Dihydrazide (AAD), 1-ethyl-3-(dimethylaminopropyl)
carbodiimide (EDC), compound 2-(N-morpholino)ethanesulfonic acid (MES), 1hydroxybenzotriazole (HOBt), iron (II,III) oxide powder (< 5 micron), Phosphate
Buffered Saline (PBS), Sigmacote®, and Bovine Serum Albumin (BSA) were all
purchased from Sigma-Aldrich (St. Louis, MO). Granulocyte Macrophage Colony
Stimulating Factor (GM-CSF), Heat shock Protein 27 (HSP27), Vascular Endothelial
Growth Factor (VEGF), Platelet Derived Growth Factor (PDGF), Stromal Cell133

derived Factor 1-α (SDF-1α), Bone Morphogenetic Protein 2, and all Enzyme-linked
Immunosorbent Assay (ELISA) kits and kit reagents were purchased from R&D
Systems (Minneapolis, MN). Lyophilized gelatin sponges (GelFoam™ sponge sheets)
were purchased from Pfizer (Groton, CT).
5.3.2 Fabrication and characterization of biomaterial system
The outer compartments of these two-compartment biomaterial systems were
made from GelFoam™ gelatin sponges. The 2 x 12 x 7 mm GelFoam™ lyophilized
sheets provided by the manufacturer were shaped into hollow cylinders with biopsy
punches (2 mm thick, 8 mm outer diameter-OD, 4 mm inner diameter-ID). In order to
image the gel’s porous structures, they were sputter-coated with gold for 30 seconds
and imaged under the Scanning Electron Microscopy (SEM) on a Zeiss SIGMA VP
Field Emission-SEM and Energy-dispersive X-ray Spectroscopy (EDS) for elemental
mapping.
The inner compartment ferrogels were made of alginate according in a similar
manner to the biphasic ferrogels described elsewhere. [21]–[23] Briefly, alginate (at
1%wt) was dissolved in MES buffer (100 mM MES and 500 mM NaCl at pH = 6.0)
with AAD and HOBt. This mixture was then mixed with iron Oxide particles (Fe3O4 <
5 μm) and 100 mg/mL EDC. Next, the mixture was cast between two sigmacotetreated glass plates separated by 2 mm spacers. During casting (~ 30 minutes), a
magnet was placed on top of the glass plate to pull the iron oxides to the top of the
ferrogel, resulting in a biphasic design. Ferrogels were then cut into 4 x 2 mm
(diameter- thickness) disks using 4-mm biopsy punches. Gels were then washed in
deionized water for 3 days with water being changed 2 to 3 times a day, this was done
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in order to remove residual reagents and let them swell. Next, to achieve a porous
structure, gels were frozen overnight at -20 °C and lyophilized. For SEM imaging,
ferrogels were cut with a sharp razor, exposing their cross section and prepped for
SEM imaging following the same protocol as described above for gelatin outer
compartments.
5.3.3 Magnetic stimulation of ferrogels
A crankshaft set up was used to magnetically stimulate the Ferrogels. This
apparatus was used for exposing ferrogels to frequencies (up to 14 Hz) but for
relatively short periods of time (see Emi et al. for a more thorough description [23]).
This setup involving the use of 0.5”x0.5” cylindrical neodymium magnets (K&J
Magnetics, Pipersville, PA) consisted of a crankshaft driven by a programmable
electric motor. The crankshaft was connected via cams to four pistons (much like a car
engine) that would move up and down in a sinusoidal manner as the crankshaft was
turned by the electric motor. Each piston contained a neodymium magnet and a
scintillation vial containing a ferrogel could be suspended directly above each of the
four pistons. Thus, when the piston was in the up position, a ferrogel would be
exposed to a strong magnetic field (measured to be 5 kGauss). When the piston was in
the down position, the magnetic field was weak (measured to be < 10 Gauss). Thus,
the speed of the motor dictated the magnetic stimulation frequency. It was determined
that this apparatus could magnetically stimulate ferrogels at frequencies up to 14 Hz.
5.3.4 Protein release studies
In order to load proteins to these gels, concentrated solutions of proteins in PBS
were made. It was determined that each outer gelatin compartment had the capacity to
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absorb 40 µL of solution which was used as the basis to calculate protein loading
concentrations (i.e., loading of 1000 ng protein would require preparation of a solution
containing 1000 ng GM-CSF in 40 µL PBS). Sigmacote-treated scintillation vials (to
prevent protein adsorption to the surface of the vials) were used as containers for these
gels. Protein carrying solutions were added dropwise to these outer compartments for
loading. Vials were capped, and gels were left at room temperature overnight for full
absorption of the protein into the gels. Release studies from the outer compartment
began the next day when gels were submerged in PBS with 1% BSA (t = 0). 1 ml
samples were collected periodically and replaced with fresh media each time.
Collected samples were stored in 1.5 mL low-adsorption tubes in the freezer. After
collecting all samples, samples were thawed and quantified for protein content (i.e.,
GM-CSF, VEGF, SDF-1α) using ELISA.
Inner compartment fabrication resulted in lyophilized alginate biphasic gels with
a layer of iron-oxide-free porous alginate on one side of the gel and an iron-oxide
saturated layer with smaller pores on the other side of the gel. The loading of these
ferrogels and release studies from them were similar to those described for the outer
gelatin compartments above. However, the absorption capacity of these ferrogels were
20 µl. Ferrogels were placed in scintillation vials with their iron-oxide free region
facing up. Next, a 20 µl solution containing protein was added to them dropwise. Vials
were capped and left in order for gels to absorb the proteins overnight. Ferrogels were
flipped over so that their iron-oxide-saturated regions faced upwards (so that a magnet
applied under the vial would deform the ferrogel in a downward motion) and then
rinsed in PBS with 1% BSA for 3 days to remove proteins that were not well
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integrated in the gel structure. Samples were then taken at different times and fresh
media was replaced at each time point. During these time course release experiments,
ferrogels were magnetically stimulated at a number of time points and at various
frequencies, depending on the experiment. ELISA was performed on the collected
samples to quantify the concentration of the released proteins from ferrogels (HSP27,
PDGF, BMP2).
5.3.5 Data representation and statistical analysis
Analysis of variance (ANOVA) with post-hoc Tukey HSD (Honestly Significant
Difference) test was performed in order to determine statistically significant
differences when multiple conditions and comparison were made. The numerical
values presented in the graphs were represent means ± standard deviations from 4
independent replicates (N = 4). P-values less than 0.05 were considered significant.
5.4.

Results and Discussion

5.4.1 Characterization of the two-compartment biomaterial system
The two-compartment biomaterial system was made of an outer gelatin
compartment and an inner biphasic ferrogel nested within the outer gelatin
compartment (Fig 3. A). The gelatin outer compartment was highly porous (Fig 3. B),
which would be desirable for allowing fast diffusive release of load proteins (due to
high surface area) and potentially efficient penetration of recruited cells. Additionally,
by virtue of being made from gelatin, this outer compartment contained cell-binding
integrins needed to have recruited cells attach the scaffold and proliferate within the
scaffold. The inner biphasic ferrogel compartment contained a Fe3O4 saturated region
on the one side of the gel and a highly porous Fe3O4-free region on the opposite side
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of the gel (Fig 3. C. i). This biphasic structure was capable of deforming in the
presence of magnetic field (Fig 3. C. ii).

Figure 3. Dual Compartment biomaterial system with porous outer compartment and
magnetically responsive inner compartment. A) Photographs of the whole system B)
Characterization of the outer compartment with SEM imaging. C) i. SEM with
elemental mapping (bottom) differentiates between Iron (yellow) and carbon (blue)
parts of the gel. ii. Ferrogels before (top) and after (bottom) stimulating with magnet.
5.4.2 Release characteristics of the outer gelatin scaffold
The outer compartment’s porous gelatin scaffold was capable of initially releasing
proteins (proteins described herein as “Factor I”) in a rapid manner. Specifically, DC
recruitment factor (GM-CSF) released mostly within the first 24 hours (Fig 4. A). The
total amount of GM-CSF release was dependent on the amount loaded in the outer
compartment (Fig 4. A: higher loadings resulted in higher amounts of cumulative
release). This rapid and adjustable initial release of DC recruitment factor may be
useful in rapidly recruiting DCs to the scaffold for biomaterials-based cancer
immunotherapy applications. Similarly, pro-angiogenic factors (VEGF) rapidly
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released from the gelatin scaffold, depleting from the gel within the first 5 hours (Fig
4. B). VEGF cumulative release was also dependent on the amount loaded into the
scaffold (Fig 4. B: higher loadings plateaued at higher levels of cumulative release).
This rapidly release of VEGF may be useful in rapidly initiating vascular sprouting
into the scaffold in applications that demand neo-vascularization (e.g., treating CVDs,
wound healing and tissue engineering applications). Finally, bone progenitor
recruitment factor (SDF-1a) released in a relatively rapid manner, plateauing 7 days
(Figure 4. C). Again, the final cumulative release values were a function of the
amount of protein loaded (Figure 4. C: higher loadings yielded higher plateau values).
This relatively rapid release profile may enable rapid recruitment of bone progenitor
cells to the scaffold for bone regeneration applications.

Figure 4. The outer compartment can rapidly release initial factors pertinent to cancer
immunotherapy, tissue vascularization, and bone regeneration. A) Top: Cumulative
release versus time of GM-CSF, Bottom: Zoomed in initial release B) VEGF, and C)
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SDF-1α from outer compartment when loaded 1000 ng (green) and 250 ng (blue) of
proteins (Colors represent different protein concentrations).
5.4.3 Release characteristics of the inner ferrogel
The inner compartment provides magnetically triggered, delayed, and on-demand
release of proteins that can be used to direct the behavior of (i.e., program) cells
recruited to the outer compartment. For example, a model cancer antigen’s (HSP27’s)
release rate drastically increase when ferrogels inner compartments are magnetically
stimulated on days 0 (Figure 5. A. inset, slope of green curve increases in the grey
shaded region of the curve compared to blue curve which is the control) or on day 3
(slope of green curve increases in the yellow shaded region compared to the blue
curve which is control), depending on when the magnetic stimulation is applied (i.e.,
on day 0 or 3, respectively). Note that the magnetic stimulation used in these studies
was at 5 Hz for 10 minutes and 1 Hz for 50 minutes in 1-hour cycle for the entire
duration of 4 hours using the piston stimulation technique. These on-demand, delayed
enhancements in release rate could be used to optimize the time point at which
recruited DCs are earnestly presented with cancer antigen for biomaterials-based
cancer immunotherapy applications.
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Figure 5. Timing of the delivery from ferrogels can be controlled by stimulating at
different time points. A) Percent Cumulative release of HSP27 when stimulated on
days 0 (dashed) and 3 (solid). B) PDGF, and C) BMP2.
Likewise, the rate of pro-vascular-maturation factor (PDGF) release could be
greatly enhanced when these ferrogel inner compartments were magnetically
stimulated (Figure 5. B). And again, the time at which magnetic stimulation was
applied enabled this enhanced release to occur at specific times (Figure 5. B:
magnetic stimulation on days 0 (grey shaded), 3 (yellow shaded), yielded
enhancements in release rates on days 0 and 3 respectively). These magnetically
triggered delays in pro-vascular-maturation factors could help optimize the time
allotted for inducing vascular sprouting before re-stabilizing the nascent vascular
network.
Finally, the rate of osteo-differentiation factor (BMP2) release could also be
enhanced when these ferrogels were magnetically stimulated (Figure 5. C: increased
slope of the green curve in the grey and yellow shaded region). Though the specific
timing of this magnetically triggered enhancement in release rate was not
demonstrated as was with PEGF and HSP27, it is likely that enhancements in release
would be generated at different time points upon magnetic stimulation at different
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time points. The ability to magnetically trigger enhancements in osteo-differentiation
factors to recruited bone progenitors may allow for optimizations in how much time is
provided to build bone progenitor populations in the scaffold prior to instructing them
to differentiate.
5.4.4 Strategies for magnetically controlling the rate of delayed release
While the delayed release capabilities outlined above may be of use in improving
the timing of deliveries in cancer immunotherapies, re-vascularization therapies, and
bone regeneration, the rate of release when magnetically stimulated is also a critical
parameter for optimization. Here, strategies were explored for using alterations in the
magnetic stimulation profile to regulate the release rate during magnetic stimulation.
A previous study demonstrated that periodically turning on and off sinusoidal
magnetic stimulations could actually improve triggered release rates compared to
continuous sinusoidal magnetic stimulation. [24] Here, this principle was investigated
further by adjusting parameters associated with pulsing the magnetic stimulation
regiment. Namely, ferrogel inner compartments were exposed to pulsed magnetic
stimulation regiments where the frequency and duration of magnetic stimulation
pulses were changed vs. time.
It was demonstrated that applying different pulsed magnetic stimulation
regiments could be used to control the rate of protein release during magnetic
stimulation. For example, after 3 days of diffusive release, ferrogels containing HSP27
were magnetically stimulated using one of two different pulsed regiments: either a
regiment switching between (i) 10 minutes of magnetic stimulation at 5 Hz followed
by 50 minutes at 1 Hz, repeated over 4 hours (Figure 6.A.i: Mag-a), or (ii) 10
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minutes’ stimulation at 10 Hz followed by 20 minutes at 2 Hz, repeated over 4 hours
(Figure 6. A.i: Mag-b). These two pulsed stimulation profiles resulted in statistically
higher release rates on day 3 compared to controls (Figure 6. A. ii and iii). While
these two pulsed stimulation profiles produced slightly different stimulated release
rates on day 3 from each other, there was no statistically significant difference
between them (Figure 6. A. iii: comparing Mag-a to Mag-b release rates). Statistical
differences may be achieved in future studies by fine-tuning the material makeup of
the ferrogel as well and the magnetic stimulation profile (e.g., different frequencies at
different times for different durations and different magnetic field intensities).

Figure 6. Rate of the delivery of proteins from ferrogels can be controlled by applying
various frequencies. A,B,C. i) Illustration of the magnetic stimulation used. A,B,C. ii)
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Cumulative release versus time for proteins when not stimulated (grey when
stimulated with magnetic profile-a (red) and magnetic profile-b (blue) A,B,C. iii)
Release rate from 72 to 76 hours for gels stimulated with nothing, magnetic profile-a
and magnetic profile-b.
The use of different pulsed magnetic stimulation regiments was more effective in
regulating the rate of PDGF release. For example, PDGF-loaded inner compartment
ferrogels were magnetically stimulated on day 3 using either a pulsed regiment that
switched between (i) 10 minutes of magnetic stimulation at 5 Hz followed by 50
minutes at 1 Hz, repeated over 4 hours (Figure 6.B.i: Mag-a), or (ii) 30 minutes’
stimulation at 5 Hz followed by 30 minutes at 10 Hz, repeated over 4 hours (Figure 6.
B.i: Mag-b). Results indicated that both pulsed stimulation profiles enhanced PDGF
release rates on day 3 compared to controls (Figure 6.B. ii and iii). Additionally, one
magnetic stimulation profile enhanced release rates compared to the other stimulation
profile (Figure 6.B. iii: Mag-a is statistically higher than Mag-b).
Based on the differences in magnetically stimulated release rates between HSP27
and BMP2, it is apparent that different proteins have different stimulated release
characteristics and that these differences are likely influenced by the interactions
between the proteins and the ferrogel’s alginate matrices. For example, BMP2
interacts highly with alginate (i.e., BMP2 is heparin-binding and alginate is heparinmimicking). In fact, when loaded with BMP2, these inner compartment ferrogels had
difficulty in releasing BMP2 at rates that were statistically different than controls. For
instance, when loaded with BMP2 and stimulated on day 3 using either a pulsed
regiment that switched between (i) 10 minutes of magnetic stimulation at 5 Hz
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followed by 50 minutes at 1 Hz, repeated over 4 hours (Figure 6.C.i: Mag-a), or (ii)
10 minutes’ stimulation at 14 Hz followed by 20 minutes at 2 Hz, repeated over 4
hours (Figure 6. C.i: Mag-b), the were no observed differences in BMP2 release rates
compared to controls (Figure 6.C. ii and iii). Again, however, it may be possible in
future studies to demonstrate magnetically triggered releases rates that are statistically
higher than controls when optimizing the material makeup of the ferrogel and the
magnetic stimulation profile (e.g., different frequencies at different times for different
durations and different magnetic field intensities).
Finally, we were able to produce a dual compartment biomaterial system that can
initially release factor I through diffusion and delay the release of factor two and only
appreciably release it when stimulated with magnetic field. Cumulative release of
GM-CSF from the outer compartment (Figure 7.A. grey curve) accompanied with
delayed release of HSP27 (Figure 7.A. Green curve) was produced with this dual
compartment system. Nonetheless, the rate of HSP27 release on day 3 was compared
with control set where there was no magnetic stimulation (Figure 7. A. blue curve,
Bottom graph shows the comparison between rate of release of HSP27). This
sequential delivery enables initial recruitment of the dendritic cells followed by
presenting them with cancer antigen when stimulated with magnetic field which leads
to larger population of activated dendritic cells. For tissue vascularization purposes,
this dual compartment system also can produce rapid initial diffusive release of VEGF
(Figure 7. B. Grey curve) from the outer compartment and have burst release of
PDGF when stimulated with magnetic field (Figure 7. B. Green curve). Rate of
release of PDGF on day 3 was significantly increased when stimulated with magnetic
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pulse (Figure 7. B. Bottom Graph. Control vs. Freq A). Furthermore, this biomaterial
system was able to release SDF-1α initially (Figure 7. C. Grey curve) and the
stimulation of the inner ferrogel on day 3 increased not only the release of SDF-1α
from the outer compartment but also increased the release of BMP-2 from the ferrogel
(Figure 7. C. Green curve). However, the rate of release of the BMP-2 was not
significantly any different than control (Figure 7. C. Bottom Graph). Which indicates
the high affinity of the BMP-2 to the alginate that explained early on in the paper.

Figure 7. Developed biomaterial system can initially release factor I in fast diffusive
manner and delay the release of a second factor until stimulated with magnetic field.
Cumulative release of A) GM-CSF, B) VEGF and C) SDF-1α vs. time (grey curve)
with delayed of factor II, A) HSP27, B) PDGF, and C) BMP-2 on day 3 when
stimulated with magnetic pulse for 4 hours at frequency A.
Ferrogel deformation under the magnetic field causes a forced outward flow of
fluid surrounding the biomaterial which not only increases the rate of release of drug
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from the ferrogel but also it increases the release of factor I loaded in the outer
compartment as well. Some applications can benefit from this effect for example in
cancer immunotherapy and bone regeneration, where we need sustained release of
initial factor to recruit cells, usually after the first 24 hours the rate of release from the
outer compartment drops significantly, this forced flow in later days increase the rate
of release in later days in order to maintain the gradient of initial factor to continue
cell recruitment. However, in some other applications like in tissue vascularization or
wound healing [24] limiting the release of initial factor in later time points is a
necessity. Therefore, the biomaterial system’s flexibility in modifying it can come in
handy to increase the affinity of the certain proteins to the binding polymer.
Subsequently to prevent unwanted release of drug from the outer compartment at later
days.
These two-compartment biomaterial systems may provide improvements in a
wide range of biomedical applications, including biomaterial-based cancer
immunotherapies, therapies involving regeneration of vascular networks, and in bone
regeneration. For example, the sequential deliveries of DC recruitment factors
followed by flexibly timed and delayed delivery of cancer antigen may enable specific
improvements in biomaterial-based cancer immunotherapies. While biomaterial-based
cancer immunotherapy has shown promising results (90% mouse survival after 3
months after being challenged with xerographic melanoma if biomaterial cancer
vaccines were implanted 14 days prior to cancer challenge),[25] when the biomaterial
vaccine was implanted in mice with existing melanomas (well-developed 13-day-old
tumors) mouse survival rates were less promising.[26] A potential area of
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improvement for these strategies lies in the timing of DC recruitment and the
presentation of cancer antigen to recruited DCs. In the biomaterial melanoma vaccine
described above, [25], [26] DCs are presented with activation factors (cancer antigen
and danger signal) as they enter the scaffold. This may result in (i) diffusive loss of
activation factors while DCs are in transient during recruitment and (ii) activation of
DCs being distributed over time (i.e., not all DCs arrive in the scaffold and are
presented with activation factors at the same time). Both of these may result in a less
intense anti-tumor response from the host. The two-compartment magnetically
responsive biomaterial system presented could enable recruitment of DCs to the outer
compartment and then delivery of activation factors to recruited DCs only after a
strong population of DCs has been recruited to the scaffold. In this manner, a strong
population of DCs can be activated, enabling a high number of activated DCs to home
to the lymph nodes, initiating a potent anti-cancer immunogenic response. Moreover,
the biomaterial system described here could enable (i) optimizations in regard to the
timing of recruited DC activation and (ii) could provide repeated/subsequent release of
activation factors through subsequent magnetic stimulations (i.e., injection-less
boosters).
The biomaterial system described here may also provide improvements for
therapies where new vasculature needs to be developed. Due to the biology outlined in
Fig 1. B, sequential release of pro-angiogenic (VEGF) and pro-maturation (PDGF)
factors is necessary for growth of new vasculature. In light of this, Richardson et al.
[27] created a biomaterial capable of delivering both VEGF and PDGF, ostensibly in
sequence, by composing a scaffold with different degradation rates. While delivery of
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PDGF alone improved vessel maturation (as measured by the distribution in vessel
diameter) compared to VEGF delivery alone, combined release of VEGF + PDGF did
not improve average vessel diameter with statistical significance over PDGF delivery
alone. This may have been due to the specific temporal profiles of VEGF and PDGF
delivery from the system. The differential degradation approach adopted by
Richardson et al. yielded VEGF and PDGF release profiles that were more of different
rates as opposed to sequential per se. That is, there was not a drastic (albeit slight)
increase in PDGF release at later time points (i.e., dramatically delayed PDGF
increases in release rate, as observed here in using magnetically responsive ferrogels).
This lack of sequential delivery may have not property coordinated the sequence of
pericyte detachment, vascular sprouting, vascular invasion, pericyte re-recruitment and
attachment, and sprout maturation required to generate mature vasculature. The
delivery profiles achieved by the two-compartment biomaterial system described here
may more properly coordinate these sequential biological events. Furthermore, the ondemand capabilities of this two-compartment system may enable critical optimization
in the timing allowed for sprouting and sprout infiltration prior to initiating vascular
maturation.
Finally, the two-compartment magnetically responsive biomaterial system
described here might be beneficial for optimizing deliveries in treating bone defects,
injuries, and diseases. Regenerating bone requires coordinated sequence recruitment,
proliferation, and differentiation events, which can each potentially be coordinated
through protein deliveries. In an attempt to coordinate these events, Lee et al. [28]
developed a biomaterial that contained two factors with the goal of enhancing the
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number of calcium phosphate matrix-producing osteoblasts: TGFβ (to enhance the
population of bone progenitors resident in the regenerative scaffold) and BMP2 (to
differentiate those bone progenitors into osteoblasts). While this strategy demonstrated
that BMP2-loaded scaffolds yielded significantly higher amounts of bone-matrix than
controls, dual-loaded BMP2/TGFβ scaffolds did not produce more bone matrix than
only BMP2-loaded scaffolds (and may in fact have yielded less bone matrix). Again,
this result may have been due to the timing of how and when these proteins were
presented to bone progenitors as they entered the scaffold from surrounding tissues.
For example, while TGFβ is known to enhance cell proliferation, it is also known that
differentiated cells do not proliferate well. [28] Thus, if cells are instructed to osteodifferentiate by being presented with BMP-2 upon entering the scaffold, they may not
proliferate well despite receiving instruction to proliferate through TGFβ presentation.
This set of simultaneous and conflicting instructions may have limited the number of
osteo-differentiate cells in the Lee et al. studies. However, if presented in sequence
(i.e., first to proliferate to a strong population while retaining their stem-like ability to
proliferate through TGFβ signaling; and then to differentiate down the osteogenic
lineage through BMP2 signaling), it may be possible to generate a more robust
population of bone-matrix-producing osteoblasts. The dual-compartment material
system presented here may afford coordination of this sequence and furthermore be
capable of optimizing the timing of this sequence for maximized bone matrix
production.
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5.5.

Conclusions
In this study, a biomaterial system was developed and its ability to sequentially

release two different proteins pertinent to three therapies was demonstrated. This
system was capable of rapidly releasing initial factors (GM-CSF, VEGF, or SDF-1a)
from a porous gelatin outer compartment that was designed to facilitate cell
infiltration. The amount of this delivery depended on the amount of the factor that was
loaded into the outer compartment. Additionally, this biomaterial system contained a
magnetically responsive ferrogel inner compartment, which was able to produce
enhanced delivery of its payload (HSP27, PDGF, or BMP2) at a time dictated by an
externally applied magnetic signal. It was also demonstrated that the rates of these
delayed and magnetically triggered protein deliveries could potential be regulated by
altering the frequencies and/or temporal profile of the magnetic stimulation itself.
5.6.

Acknowledgements
This research was funded by a Medical Research Grant from the Rhode Island

Foundation (20144262), an Early Career Development Award from the Rhode Island
IDeA Network of Biomedical Research Excellence (RI-INBRE, NIH/NIGMS
2P20GM103430), a 3M Company Non-Tenure Faculty Award (32976949), and a
grant from the National Science Foundation (NSF-CBET 1063433). The authors
would like to thank Irene Andreu at the RI consortium for Nanoscience &
Nanotechnology for help with SEM imaging.

151

5.7.

References

1 Gombotz WR, Pettit DK. Biodegradable Polymers for Protein and Peptide Drug
Delivery. 1995;345(206):332-351.
2 Kearney CJ, Mooney DJ. Macroscale delivery systems for molecular and cellular
payloads. Nat Mater. 2013;12(11):1004-1017.
3 Singh A, Peppas NA. Hydrogels and scaffolds for immunomodulation. Adv Mater.
2014;26(38):6530-6541.
4 Facts C. Cancer Facts & Figures 2017. 2017.
5 Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev
Immunol. 2004;4(4):249-259.
6 Li WA, Mooney DJ. Materials based tumor immunotherapy vaccines. Curr Opin
Immunol. 2013;25(2):238-245.
7 Kim J, Mooney DJ. In vivo modulation of dendritic cells by engineered materials:
Towards new cancer vaccines. Nano Today. 2011;6(5):466-477.
8 Kochanek KD, Murphy SL, Xu J. National Vital Statistics Reports Deaths : Final
Data for 2014. 2017;65(4).
9 Kottke TE, Giles WH, Capewell S. Explaining the Decrease in U.S. Deaths from
Coronary Disease, 1980–2000. 2007:2388-2398.
10 Werner S, Grose R. Regulation of wound healing by growth factors and cytokines.
Physiol Rev. 2003;83(3):835-870.
11 Eming SA, Martin P, Tomic-canic M, Park H, Medicine R. Wound repair and
regeneration: Mechanisms, signaling, and translation. Sci Transl Med. 2016;6(265):136.

152

12 Henkel J, Woodruff MA, Epari DR, et al. Bone Regeneration Based on Tissue
Engineering Conceptions – A 21st Century Perspective. Nat Publ Gr. 2013;1(3):216248.
13 Lee KY, Peters MC, Anderson KW, Mooney DJ. Controlled growth factor release
from synthetic extracellular matrices. Nature. 2000;408(6815):998-1000.
14 Services H. Bone Health and Osteoporosis A Report of the Surgeon General.
15 Boyan BD, Baker MI, Lee CSD, Raines AL. Bone Tissue Grafting and Tissue
Engineering Concepts. Elsevier Ltd.; 2011.
16 Younger EM, Chapman MW. Morbidity at bone graft donor sites. 1989;(January
1982):3-5.
17 Mehta M, Schmidt-bleek K, Duda GN, Mooney DJ. Biomaterial delivery of
morphogens to mimic the natural healing cascade in bone. Adv Drug Deliv Rev. 2012;
64 (12) :1257-1276.
18 Ennett AB, Kaigler D, Mooney DJ. Temporally regulated delivery of VEGF in
vitro and in vivo. 2006.
19 Chen F, Chen R, Wang X, Sun H, Wu Z. Biomaterials In vitro cellular responses to
scaffolds

containing

two

microencapsulated

growth

factors.

Biomaterials.

2009;30(28):5215-5224.
20 Dual delivery of an angiogenic and an osteogenic growth factor for bone
regeneration in a critical size defect model. Bone. 2008;43(5):931-940.
21 Cezar C a, Kennedy SM, Mehta M, et al. Biphasic Ferrogels for Triggered Drug
and Cell Delivery. Adv Healthc Mater. 2014:1-8.

153

22 Kennedy S, Roco C, Déléris A, et al. Improved magnetic regulation of delivery
profiles from ferrogels. Biomaterials. 2018;161:179-189.
23 Emi T, Barnes T, Orton E, et al. Pulsatile Chemotherapeutic Delivery Profiles
Using Magnetically Responsive Hydrogels. ACS Biomater Sci Eng. 2018.
24 Tolouei AE, Dülger N, Ghatee R, Kennedy S. A Magnetically Responsive
Biomaterial System for Flexibly Regulating the Duration between Pro- and AntiInflammatory Cytokine Deliveries. Adv Healthc Mater. 2018;7(12).
25 Ali O a, Huebsch N, Cao L, Dranoff G, Mooney DJ. Infection-mimicking materials
to program dendritic cells in situ. Nat Mater. 2009;8(2):151-158.
26 Ali O a, Emerich D, Dranoff G, Mooney DJ. In situ regulation of DC subsets and T
cells mediates tumor regression in mice. Sci Transl Med. 2009;1(8):8ra19.
27 Richardson TP, Peters MC, Ennett B, Mooney DJ. Polymeric system for dual
growth factor delivery. Nat Biotechnol. 2001;19(11):1029-1034.
28 Lee K, Weir MD, Lippens E, et al. Bone regeneration via novel macroporous CPC
scaffolds in critical-sized cranial defects in rats. Dent Mater. 2014;30(7):e199-e207.

154

CHAPTER 6

CONCLUSION

6.1.

Importance and Summary
This doctoral research is focused on two broad applications of hydrogel-based

biomaterials—cancer research and tissue engineering. The primary goal of this
dissertation was to develop biomaterial systems that can produce controlled drug
delivery profiles critical to improving the quality of therapeutic treatments in these
areas. This research aimed to i) investigate the impact of dynamic and sequential
release profiles of anticancer agents to B16-F10 melanoma cancer cells, ii) develop
stimuli-responsive hydrogels systems to release therapeutic molecules when subjected
to external ultrasonic or magnetic stimulation, iii) explicitly characterize the
biomaterials to improve our understanding of their performance (and limitations of
their performance), thus expanding their utility in cancer therapies, tissue engineering
strategies, and beyond.
In Chapter 1, the motivation behind this work, present knowledge and problem in
this field were discussed. Then the principal objectives were mentioned to address this
problem.
Chapter 2 contained the elaborate discussion on current ultrasound-based drug
delivery systems. The principal mechanisms underlying drug release from
biomaterials by ultrasound were investigated as a function of various tunable
properties. For instance, the rate of payload release by ultrasound stimulation is a
function of ultrasound intensity, duration, pulse number, etc. Therefore, several
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strategies were suggested to remotely control the deliveries from biomaterial scaffolds
by exploiting those parameters.
Chapter 3 presented ionically crosslinked hydrogels that can release various
molecular payloads when subjected to ultrasound stimulations. These studies
demonstrated that release rates were a function of molecular size, polarity, charge,
hydrogel properties (polymer and crosslinker concentrations), and stimulation
properties (intensity, timing, duration, pulse number). These characterizations were
used to design studies and demonstrate the ability to i) deliver mitoxantrone in a
pulsatile manner, and ii) sequentially deliver 5-fluorouracil and irinotecan, both while
retaining the hydrogel integrity and maintaining moderate temperatures.
In Chapter 4, the importance of pulsatile chemotherapeutic deliveries was
investigated. It was demonstrated that pulsatile delivery profiles significantly reduced
B16-F10 melanoma cell populations compared to the more consistent delivery profiles
produced by traditional hydrogel materials. Then, a magnetically responsive biphasic
ferrogel was used to produce these optimized pulsatile delivery profiles. Furthermore,
it was demonstrated that the applied magnetic field frequency could be used to
regulate the characteristics (timing and rates) of the pulsatile delivery profile.
In Chapter 5, multiple sequential cytokine deliveries were investigated that are
pertinent to regulating biological processes in tissue engineering and cancer
immunotherapy applications. These sequential delivery profiles were demonstrated
with a low frequency, benign magnetic field. A two-compartment hydrogels system
was developed where the outer gelatin compartment released payload in a burst profile
and inner ferrogel compartment released another payload in an on-demand, delayed
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manner. These studies included sequential release profiles of a) GM-CSF and HSP-27
(for cancer immunotherapies), b) VEGF and PDGF (for vascular regeneration), and c)
SDF-1α and BMP-2 (for bone regeneration applications).
6.2.

Future Directions
The stimuli-responsive biomaterial systems presented in this dissertation have a

strong potential in improving cancer treatment and tissue engineering strategies by
enabling pulsatile and sequential deliveries. However, future work is necessary to
optimize and translate the use of these materials fully. Further optimizations will
include testing a broad range of pulsatile and sequential delivery profiles (different
rates, stimulation duration, total treatment duration, the timing of adding other agents,
the timing of stimulation off periods). Additionally, work must be performed on other
cancer cells (other than melanomas), 3D tumor spheroids (the studies here only
involved 2D cultures), and combinations of other anticancer agents (irinotecan, 5FU,
leucovorin, oxaliplatin, etc.).
Successful application of implantable biomaterial constructs in vivo will also be
necessary for moving forwards using these materials in cancer and tissue engineering
treatments. Beyond the clinically applicable aspects of this work, the use of these
stimuli-responsive materials in vivo may also provide a great deal of investigative
utility. Being able to easily alter the timing and sequence of multiple therapeutics
between experiments may greatly streamline experiments designed to enhance our
knowledge of cancer and regenerative biology.
Beyond therapeutic applications, porous hydrogels have potential utility in
wastewater treatment and remediation. There is a strong need for a low-cost
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wastewater treatment that are portable and reusable. Polymeric hydrogels made with
graphene oxide nanoparticles have the potential to sequester cationic contaminants.
Hydrogels saturated with contaminants can be transported and purged using chemicalfree desorption, potentially through stimulation if the materials were endowed with
stimuli-responsive capabilities. Electroconductive hydrogels, for instance, can be
employed to selectively sequester, transport and reuse contaminants based on their
polarity, magnitude, and frequency of the electronic signal used to excite the material.
Thus, these materials have broad potential in critical therapeutic applications, but they
also have potentially fruitful applications beyond medicine. Such broad potential
utility strongly warrants future investigations on the use of stimuli-responsive
hydrogel materials.
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S.1. Loading mitoxantrone in ferrogels and rinsing
In order to assess how much mitoxantrone was incorporated into ferrogels after
loading, how saturated the gels were, and how much mitoxantrone remained after
rinsing, supplemental experiments were conducted. Ferrogels were loaded with
various amounts of mitoxantrone (25, 50, 125, 250, and 500 µg) by adding
concentration solutions (65 µL) of mitoxantrone dropwise to the iron-oxide-free,
alginate region of ferrogels (similarly as described in Section 2.6). First, to determine
the relative degree of mitoxantrone saturation in these ferrogels, mitoxantrone-loaded
ferrogels were allowed to soak in 1 mL release media until they equilibrated, taking 5
days. For various amounts of mitoxantrone loading, the amount released from day 0 to
equilibrium could be quantified vs. time (Figure S1A), including the 125 µg loading
we adopted in our pulsatile release studies (Figure S1A, red curve). From these data,
the amount of mitoxantrone remaining in the ferrogels could be plotted vs. time
(Figure S1B), which could also be normalized by the substrate’s mass (i.e., the dry
weight of the ferrogels, Figure S1C). Thus, at equilibrium, the normalized amount of
mitoxantrone bound to the gel could be plotted for various amounts of mitoxantrone
loading (a partial isotherm curve, Figure S1D). It can be seen that the 125 µg loading
(Figure S1D, red point) we adopted in our pulsatile S2 release studies is not in the
saturation region of this isotherm curve, and thus represents a loading that leaves
additional binding sites for mitoxantrone if it were to be loaded with higher amounts
of mitoxantrone.
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Figure S1. The 125 µg of mitoxantrone used in our pulsed delivery studies does not
represent a loading that saturated ferrogels with mitoxantrone. (A) Mitoxantrone
diffusively released over 5 days with no media changes at the indicated mitoxantrone
loadings. (B) Mitoxantrone remaining in ferrogels vs. time for 5 days. (C)
Mitoxantrone remaining in ferrogels vs. time normalized by the dry mass of ferrogels.
(D) Mitoxantrone to ferrogels at equilibrium vs. loading concentration normalized by
ferrogel dry mass. In parts A-D, red curves represent the loading used in pulsed
delivery studies (125 micrograms per gel). N = 4.
In order to quantify the amount of mitoxantrone loaded in ferrogels, experiments
were conducted to load ferrogels with various amounts of mitoxantrone (including 125
µg per gel) and then digest them so that the amount recovered could be sampled
(Figure S2A). Results demonstrated that over 80% of the 125 micrograms of
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mitoxantrone was recovered after gel digestion (Figure S2B). Additionally, similar
experiments were conducted to quantify how much S3 additional mitoxantrone was
lost in the 1-hour rinse (Figure S2C). Results indicated that very little mitoxantrone
was rinsed off during the 1-hour rinse. For ferrogels loaded with 125 micrograms of
mitoxantrone, an average of 101.4 micrograms remained in the gels prior to
experimentation.

Figure S2. When loaded with 125 µg of mitoxantrone, over 80% of the drug
integrated into the gels and very little in addition to that was rinsed off during 1-hour
rinses. (A) Schematic of procedure for quantifying amount of mitoxantrone loading.
(B) Percent of mitoxantrone recovered after loading vs. amount loaded. (C) Schematic
of procedure for quantifying amount of mitoxantrone rinsed off during 1-hour rinses.
(D) Amount of mitoxantrone recovered after loading (light bars) and amount
remaining after 1-hour rinses (dark bars). For parts A-D, red data represent data
obtained using 125 micrograms of loading. N = 3.
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S.2. Movies of magnetic stimulation system.
<< MovieS1.mov >>
Movie S1. Movie of the custom magnetic stimulation system operating at 0.1 Hz.
<< MovieS2.mov >>
Movie S2. Movie of the custom magnetic stimulation system operating at 1 Hz.
<< MovieS3.mov >>
Movie S3. Movie of the custom magnetic stimulation system operating at 10 Hz
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S.1. Abstract
Biphasic ferrogel has shown promise in drug delivery and tissue engineering
applications. It’s biocompatibility, and porous structure enable better drug molecule
and cell retention. The release rates of therapeutic molecules can be tuned by various
parameters to achieve temporal profiles. Magnetic stimulation frequency is one of
those parameters used for regulating release rates. However, when ferrogels are
exposed to repeated pulsations, their responses vary depending on magnetic
stimulation frequencies. The purpose of this study was to investigate the effect of
mechanical properties and rheology of ferrogels on therapeutic molecule delivery
application when exposed to various dynamic compression frequencies. Here, we
dynamically compressed magnetically responsive biphasic alginate ferrogels at 0.04
mm/mm constant strain from 0.01 Hz to 3 Hz compression cycle frequencies. Finally,
experiments were performed to study the release rates of various model
macromolecules (dextrans), chemotherapeutics, and protein signaling factors from
ferrogels when exposed magnetic stimulation frequencies from 0.1 Hz to 14 Hz.
Therefore, this letter highlights the impact of dynamic compressions on the
viscoelastic behavior of ferrogels to optimize a suitable operating region for real-time
control in the clinical application.
S.2.

Introduction
Implantable magnetically responsive hydrogels have shown potential for

biomedical applications, such as cancer chemotherapy, wound healing, muscle and
bone regeneration applications [1-7]. The biological system precisely operates by a
sequence of instructions for a tissue regeneration event (vascularization, injury,
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fracture healing) [8-11]. These ferrogels has reported hosting cells by carrying cell
recruitment and differentiation factors in the scaffold [1, 3]. Additionally, for cancer
therapy, ferrogels showed encouraging results by providing dynamic temporal
delivery profiles [4, 6]. Ferrogels are soft that can undergo large deformations when
subjected to magnetic stimulation and return to its original shape when magnetic
stimulation reverts [3-4]. The main advantage of these ferrogels is they can establish a
local gradient of molecules by triggering the payload release in repeated on/off cycles
in an on-demand manner. They respond to an alternating magnetic field in such a way
amenable for better payload release. Their macroporous structure allows for transport
of molecules from pores to the gel matrix when equilibrates then finally release out
from the ferrogel scaffold. The rate of payload release from the ferrogels was reported
to be regulated by tuning the magnetic field frequencies. Depending upon the size,
charge, polarity, and affinity of the molecular payloads some frequencies that can
result in greater release rates than other frequencies [4]. For example, low-affinity
drug molecules can be released at higher rates at 50 Hz frequency than at 200 Hz
frequency [4].
Ferrogels can be compressed for therapeutic applications using a simple handheld magnet or by a graded magnetic field non-thermally which is critical for sensitive
biologic payloads. Although ferrogels convectively purge out molecular payloads, it is
not well understood why the release rate varies depending on the frequencies. For
instance, some lower frequencies might result in higher release rates when compared
to the higher frequencies [4]. Therefore, we hypothesized that the compression
frequencies could potentially influence the rheology of ferrogels. While there are few
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viscoelastic properties for hydrogels found in the literature, very few experimental
results are available for ferrogels. Additionally, there is growing evidence that
anticancer agents delivered from ferrogels by periodic pulsations can result in
significant tumor growth reduction [6, 12-14]. Therefore, in-depth understanding of
the viscoelastic behavior of ferrogels is essential for selecting the magnetic stimulation
parameters (frequency, the amplitude of deformation, duration) that will not
compromise the structural integrity. Besides, the temperature of the freeze-dried
ferrogels was reported to influence the pore size [1]. While pore size of ferrogels is a
critical parameter for payload retention and transport, the lack of therapeutic molecule
release data from ferrogels freeze dried at different temperatures limit its selection for
drug and cell delivery applications. Therefore, this letter investigated i) the mechanical
properties of ferrogels freeze dried at two different temperature (-20oC and -80oC), ii)
how frequency can impact their rheology, and finally, iii) presented magnetically
therapeutic molecule release experiments for strategic implementation.
S.3.

Results and Discussion
We fabricated ferrogels using 1 wt% alginate polymer, crosslinked with 2.5 mM

AAD (adipic acid dihydrazide) and 7 wt% iron oxide (Fe2O3) particles previously
optimized for maximum deformation [3-4]. Two types of biphasic ferrogels were
fabricated by using -20oC and -80oC freeze drying temperatures. The ferrogels consist
of iron oxide-laden region transitioned to deformable and macroporous alginate region
(Figure S1A, top photographs and bottom SEM images). Their SEM images revealed
higher pore size of 275 µm for -20oC ferrogels than 175 µm for -80oC ferrogels
(Figure S1B (i), blue and green bars). Higher pore interconnectivity of 71% and 63%
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resulted that were consistent with literature reported that -20oC and -80oC ferrogels
respectively tested by water wicking method (Figure S1B (ii)). The Young’s modulus
of ferrogels showed that -20oC ferrogels were softer and had less toughness than -80oC
ferrogels (Figure S1C). It was because of the smaller pore size of the -80oC ferrogels,
they potentially were stiffer than the -20oC ferrogels.

Figure S1: -20oC and -80oC ferrogels shown different morphological and
mechanical properties. A) photographs and SEM images of ferrogels with elemental
mapping. B) Pore size calculated by ImageJ software (i) and pore interconnectivity
measured by water wicking test (ii). C) Mechanical properties of ferrogels, Young’s
modulus (i), and toughness (ii). Asterisk (*) indicates statistical differences where pvalue < 0.05 calculated by student t. test.
To determine the viscoelastic behavior of the ferrogels, we conducted dynamic
compression testing of submerged ferrogels at a constant strain. -20oC and -80oC
ferrogels were hydrated overnight with PBS. Fully swollen ferrogels were subjected to
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sinusoidal mechanical compressions at 0.04 mm/mm constant strain from 0.01 Hz to 3
Hz compression frequencies while submerged in the 20 mL of PBS buffer solution.
Note that, 0.04 mm/mm strain amplitude was chosen to remain in the linear
viscoelastic region. Also, at above 5 Hz frequency, the mechanical compression
testing instrument was not being able to maintain the constant strain. Therefore, to
maintain consistency, 0.01 Hz to 3 Hz cyclic frequency region was chosen. At lower
frequencies of 0.01 Hz to 1 Hz, ferrogels underwent constant strain and stress that
started to take a downward trend at above 1 Hz (Figure S2A). -80oC ferrogels were
found to hold more stress than -20oC ferrogels as predicted from its Young’s moduli
(Figure S2B, blue and green lines). The phase lag between the strain and stress
seemed to have a decreasing trend (Figure S2C) which is consistent with the
simulated results found elsewhere [15]. 75o phase lag existed at 0.01 Hz frequency,
which started to go lower and maintained a uniform lag of 60o beyond 0.5 Hz
frequencies for both types of ferrogels. It was because ferrogels behaved more viscous
at lower frequencies but started to gain its elasticity at higher frequencies. Two kinds
of ferrogels shown uniform storage moduli of 15 kPa and 18 kPa for -20oC and -80oC
ferrogels respectively at frequencies below 1 Hz and it increased to > 20 kPa beyond 1
Hz (Figure S2D, blue and green lines at ~1 Hz). The reason for this might be ferrogels
were forced to equilibrate at a faster rate with increasing compression frequencies. The
viscous property of the -80oC ferrogels was also seemed to reduce with the increase of
frequencies as expected (Figure S2E). While -80oC ferrogels behaved more elastic
with increasing frequencies, the -20oC ferrogels had shown a slight increase in its
viscous behavior at frequencies beyond 1 Hz. The rate of convectively purging of
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liquids from larger pores of -20oC ferrogels and then reverting to their original shape
was slower compared to purging liquids from smaller pores of -80oC ferrogels.

Figure S2: Rheology of ferrogels changed when subjected to cyclic compressions,
A) strain vs. frequency, B) stress vs. frequency, C) phase lag vs. frequency, D) storage
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moduli vs. frequency, E) loss moduli vs. frequency, and F) damping vs. frequency.
Blue and green lines represent data for -20oC and -80oC ferrogels respectively.
However, the damping or loss of energy seemed to be had similar trends for both
ferrogels (Figure S2F, blue and green lines at above 1 Hz). They maintained a
constant value up to 0.05 Hz frequency and went to a downward direction beyond that.
Freeze dried ferrogels were subjected drug release tests at various magnetic
frequencies to determine the rate of releases at different frequencies. Ferrogels were
loaded with dextrans, chemotherapeutic agents or protein signaling factors to
investigate their release characteristics as a function of ferrogel freezing temperature
and magnetic frequencies. Ferrogels were reported to remotely trigger therapeutic
molecule release [3, 5-6]. We hypothesized that different freezing temperature might
result in different release rates. To test this hypothesis, we at first studied the release of
four different model macromolecules (FITC dextrans): relatively small dextrans of 3-6
kDa and larger dextrans of 70 kDa. Additionally, to investigate the impact of charge,
uncharged dextrans were used as well as Diethylaminoethyl (DEAE) cationic
dextrans.

Then

we

tested

for

small

molecular

weight

chemotherapeutics

(mitoxantrone, irinotecan, and 5-fluorouracil), large molecular weight proteins
(Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor
(PDGF)). 64 µL of dextran, drug or protein solutions containing 125 µg/gel drug or
dextran or 65 ng/gel protein were loaded to a ferrogel. This volume and concentration
of molecules were chosen because they were previously found this author’s previous
work to be optimum for a ferrogel without saturating it [6]. Gels were rinsed with 1
mL of PBS buffer for 1 h to reduce the unincorporated molecules that will result for
171

diffusive release without any stimulations. Ferrogels were then exposed to a graded
magnetic field for 10 min at magnetic frequencies from 0.05 Hz to 14 Hz. This region
of frequencies was chosen because our custom magnetic system operated in this
region.

Figure S3: Ferrogels released model macromolecules when exposed to magnetic
stimulation. FITC dextran release rate vs frequency plots (A) small neutral (3-6 kDa
dextran), (B) large neutral (70 kDa dextran), (C) small cationic (DEAE 3-6 kDa
dextran), (D) large cationic (DEAE 70 kDa dextran). Asterisks (*) indicate levels of
statistical differences for release rates compared to -20oC and -80oC ferrogels. Dashed
lines indicate non-stimulated release rates.
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Small and large molecular weight dextrans of neutral charge seemed to have
higher release rates at higher frequencies than non-stimulated diffusive release, where
release rates were higher from -80oC ferrogels than from -20oC ferrogels (Figure S3A
and B, green and blue lines). Small-cationic dextrans had lower release rates
compared to neutral dextrans where frequencies being less influential (Figure S3A
and C). Release rates of large-cationic dextran were very low which were almost the
same as the non-stimulated diffusive release (Figure S3D, solid and dashed lines).
The cationic dextrans electrostatically interacted with the negative charges of polymer
alginate matrix. Thus, cationic dextrans released at a lower rate compared to their
neutral counterparts. The freezing temperature of ferrogels did not impact the release
rates of cationic dextrans (Figure S3D). This was because of the higher electrostatic
affinity to the polymer matrix might overcome the external force of the magnetic field.
Whereas, neutral dextran molecules transported throughout the matrix shown to have
greater mobility when stimulated.
Release experiments with four model macromolecules helped to understand the
release characteristics of actual therapeutic agents. Next, we loaded the ferrogels with
mitoxantrone, irinotecan, and 5-fluorouracil (Figure S4A (i)-(iii)). All of those have
lower molecular weight with various charges and polarity: 5FU (130.1 Da, neutral
charge), irinotecan (586.7 Da, +1 charge), and mitoxantrone (444.5 Da, +2 charge).
We, therefore, hypothesized that smaller and polar drug molecule would release at a
faster rate from ferrogels. Indeed, 5FU being the lowest of these three anticancer
agents, showed less sensitivity to magnetic stimulations and resulted in slightly higher
release rates than non-stimulated diffusive release for any frequencies (Figure S4A
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(i), solid and dashed lines). Because of its smaller size and water solubility, the
convective transport from the molecules become easier. However, release rates from 800C ferrogels shown to have a downward trend with increasing frequencies (Figure
S4A (i), solid green and blue lines above and below 5 Hz). Mitoxantrone has shown to
get triggered release at higher frequencies (1 Hz to 14 Hz) which is consistent with the
ferrogels dynamic mechanical properties of being progressively elastic at higher
frequencies.
-20oC and -80oC ferrogels had shown oppositely higher and lower release rates at
1 Hz and 14 Hz frequencies (Figure S4A (iii)). At 1 Hz, -20oC and -80oC ferrogels
released at ~20 µg/hr and ~40 µg/hr rates respectively, whereas, at 14 Hz, they
released at ~50 µg/hr and ~30 µg/hr rates respectively. Irinotecan, on the other hand,
has relatively higher molecular weight than others shown higher release rates from 200C ferrogels than from -800C ferrogels while being less sensitive to the magnetic
field frequencies (Figure S4A (ii)). The bigger pore size of the -200C ferrogels might
attribute to the higher release rates. The irinotecan release rates were generally higher
from stimulated gels than their non-stimulated counterparts at any frequencies (Figure
S4A (ii), solid and dashed lines).
To examine how the frequency of magnetic stimulations effects on the VEGF and
PDGF release, ferrogels were loaded with 65 ng/gel VEGF or PDGF. Tests were
conducted using the same manner used for dextrans and anticancer agents. Both
VEGF and PDGF resulted in significantly higher release rates from -200C ferrogels.
The bigger pores might also facilitate greater release rates from -200C ferrogels.
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Figure S4: Magnetic stimulation also triggered the release of chemotherapeutics
and proteins from ferrogels. (A) Release rate vs. frequency plots of
chemotherapeutics: 5-fluorouracil (i), irinotecan (ii), and mitoxantrone (iii). (B)
Release rate vs. frequency plots of proteins: VEGF (i), and PDGF (ii). Asterisks (*)
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indicate levels of statistical differences for release rates compared to -20oC and -80oC
ferrogels. Dashed lines indicate non-stimulated release rates.
The study presented in this letter focused on the impact of various magnetic
stimulation frequencies on the viscoelastic properties of the ferrogels and diverse
payload release. The evidence of effective temporal release profiles on cancer therapy
and tissue engineering applications motivates to investigate the viscoelastic behavior
of ferrogels [11, 16-20]. Therefore, the potential use of understanding the rheology of
ferrogels are critical for finding out the optimal region of operation. For example, a
release strategy can be developed where, burst release occurs at frequencies > 1 Hz,
whereas a delayed release might happen by more slow/passive stimulations at
frequencies < 0.05 Hz. Besides, for a multi-drug sequential release, a twocompartment ferrogel consisted of -800C ferrogel as outer compartment and -200C
ferrogel as inner compartment can be designed from optimizing the release rates of
chemotherapeutics found in this work. It can provide release of one molecule
significantly higher at 1 Hz from the outer compartment and other molecules from the
inner compartment at 14 Hz frequency on a user-defined time. Another potential use
of the ferrogels was reported for muscle regeneration. These ferrogels can be effective
to regenerate 2-2.5% of the injured muscle tissue by two weeks without any bioagents
[2]. The viscoelastic properties of ferrogels can optimize this application of ferrogels
by varying their thickness, size, crosslinker and polymer concentrations, and
maximum deformations, etc.
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S.4.

Conclusions
This study investigated the mechanical and viscoelastic properties of ferrogels

freeze dried at -200C and -800C. Then this paper went on to demonstrate the triggered
release of various molecules (model macromolecules, chemotherapeutics, and protein
signaling factors) in the presence of external magnetic stimulation. Finally, release
rates were found to be a function of frequencies and freezing temperature of ferrogels
which can potentially be used for selective therapeutic molecule deliveries.
S.5.

Experimental

S.5.1 Ferrogel fabrication, imaging, and porosity
Magnetically responsive hydrogels were fabricated from purified alginate through
dialysis (3500 MW cutoff, Spectrum Labs, Compton, CA), activated charcoal
treatment, filtration, and lyophilization. In a previously described manner, alginate was
dissolved in MES buffer (pH = 6.5) with AAD, and iron oxide powder to form a
solution containing 7 wt % iron oxide, 1 wt % alginate, 2.5 mM AAD crosslinker [34]. The resulting structure was an 8 x 2 mm cylindrical dehydrated, macroporous,
biphasic ferrogel. After rinsing the gels for three days, they were kept in -200C and 800C freezer (on previously frozen 24-well plates at -200C and -800C temperatures).
Structural analyses of freeze-dried ferrogels were performed using Scanning Electron
Microscopy (SEM) with a Zeiss SIGMA VP Field Emission-Scanning Electron
Microscope (FE-SEM) equipped with an energy dispersive X-ray spectroscopy EDS
detector for elemental mapping. Backscattered electron imaging was done using
identical conditions at an accelerator voltage of 20 keV and a chamber pressure of
5×10-6 torr. 17.2 nm thickness of gold sputter coating was applied to the ferrogels for
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imaging. Pore size was measured using ImageJ software, and pore interconnectivity
was measure by water wicking test.
S.5.2 Ferrogel mechanical characterizations and cyclic compressions
Fully swollen ferrogels were subjected to compression tests using Instron 3345
(Norwood, MA) single column apparatus with a strain rate of 2 mm/min until reaching
90% strain to avoid the risk of damaging the instrument. Engineering stress and strain
were recorded from Instron Bluehill 3 software package. Young’s modulus was
calculated from the linear portion of the stress-strain curve according to Hooke’s law:
σ = Eε. Toughness was calculated from the area under the stress-strain curve.
Ferrogels were compressed cyclically using LFS-200N-A BiSS (Bangalore, India)
material testing machine. Gels were subjected to 10 min compression cycles at 0.01
Hz to 3 Hz at 0.04 mm/mm maximum strain in a closed chamber of 20 mL PBS buffer
solution. Relative force and displacement vs. time data were collected from the BiSS
MTL software package. Relative force and displacement data were used to calculate
the strain, stress, phase lag, storage moduli, loss moduli and, damping vs. frequency.
S.5.3 Therapeutic molecule release studies
Lyophilized ferrogels were loaded with 65 µL solution of 125 µg/gel dextran or
anticancer agents or 65 ng/gel proteins and left in a closed cap scintillation vial
overnight. To remove unincorporated molecules, ferrogels were then soaked in 5 mL
of PBS for 1 hour. Immediately the following rinse, gels were placed in 1 mL of PBS,
and the release study was initiated. Ferrogel-containing scintillation vials were placed
on top of a custom magnet stimulation system described previously [6] and exposed to
0 to 5.6 kGauss graded magnetic stimulation signals (or no signal for control
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experiments) at frequencies between 0.1 to 14 Hz). Samples were taken after 10 min
stimulation by fully removing the 1 mL of PBS, reserving it for later analysis. The
concentration of FITC-dextran release was quantified using fluorescence ex/em at 495
nm and 525 nm in a BioTek Cytation3 microplate reader against a standard curve. The
concentrations of mitoxantrone, 5-fluorouracil and irinotecan release samples were
quantified by measuring optical absorbance at 610 nm, 350 nm, and 370 nm,
respectively, on the plate reader against a standard curve. ELISA was used to measure
the concentration of signaling factor release (VEGF and PDGF).
S.5.4 Data representation and statistical analysis
All quantitative data presented here are represented by means ± standard
deviation, unless otherwise specified. For all statistical analyses, student t. test was
used and p-values of less than 0.05 being our benchmark for statistical significance. *,
**, ***, and **** indicates statistical significance of p < 0.05, 0.01, 0.001, and 0.0001
respectively. n.s. indicates no statistical significance. (p > 0.05).
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